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SVZ  : Sub ventricular zone 
MPE   : Myxopapillary ependymoma 
GFAP  : Glial Fibrillary Acidic Protein 
WHO   : World Health Organisation 
IHC   : Immunohistochemistry 
ICMR  : Indian Council of Medical Research 
SEER  : Surveillance, Epidemiology and End Result Program 
CBTRUS  : Central Brain Tumour Registry of the United States 
CNS   : Central Nervous System 
PA  : Pilocytic Astrocytoma  
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DA  : Diffuse Astrocytoma 
ODG  : Oligodendroglioma 
EPEN  : Ependymoma 
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GBM  : Glioblastoma Multiforme 
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IDIM             :        Intradural Intramedullary 
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ABSTRACT 
INTRODUCTION  
                     Glial tumors are a varied   group of neoplasm. CD117 is a protooncogene  
encoded  tyrosine kinase receptor.  It is expressed usually in some normal tissues and  
in neoplasms  like GIST.(gastrointestinal stromal tumors) . Treatment with inhibitors 
of receptor for tyrosine kinase namely imatinib  is proved successful  in cases  like 
gastrointestinal stromal tumour which are  CD117- positive. Likewise   aim  of this 
study  is to evaluate   the expression of CD117 in  tumors  of glial origin,to prove the 
marker  as  useful marker for  diagnostic purpose  and also  therapeutic purpose.This 
study also includes  analysis   of   CD117  expression in  glial  tumor subtypes and 
grades. 
AIMS AND OBJECTIVES 
 
To study the expression of CD117 In glial tumors , to  correlate the percentage 
of expression of cd117 with tumor type and grade, to evaluate CD117 as a diagnostic 
and therapeutic tool and also  to study the age, sex, and site  predeliction of  different 
types of  gliomas. 
                            MATERIALS AND METHODS 
This is  a retrospective  study,during the period from jan 2013-dec2014  .A total 
of 263 gliomas  samples were received.out of these  cases 50 representative cases 
were selected.Corresponding paraffin blocks were   subjected to H&E staining and 
immunohistochemical analysis by primary marker CD117  .The results  were 
tabulated in a master chart ,also recorded with photographs and were statistically 
analysed. 
RESULTS: 
CD117 was positive in 54% of total cases. CD117 expression was seen maximum 
in High grade  tumours(66.8%) with statistical significance of (P <0.05). Highest 
CD117 expression score  was seen in WHO grade III tumours with  statistically 
significance  ( P=0.011*).The cells with  marked nuclear pleomorphism showed 
increased CD117 expression,with statistical significance(P< 0.042).  CD117 
expression was high in cases with high  cellularity    showing  statistically  
significance.(P < 0.041). Highest CD117 positivity was seen in 61-80 years age ,in 
females more than males,and in left hemisphere than right. 
 
CONCLUSION 
Incidence of gliomas are on the rise.CNS tumours are different from other 
tumours as  treatment and prognosis depends on the site of the tumour and  most 
tumours are less amenable for surgery. Our study shows CD117 is expressed 
remarkably in high grade tumours than low grade. Hence CD117 can be used as a 
perfect tool to identify these tumours and thus make them amenable to chemo therapy 
with tyrosine kinase inhibitor, like Imatinib., which is already proven and in vogue in 
gastrointestinal stromal tumour.Hence  this study opens the vision on targeted therapy  
in gliomas for high grade tumours. 
          KEY WORDS : CD117,gliomas,high grade tumours, GIST, imatinib.   
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INTRODUCTION 
 
 Tumours of central nervous system pose a major challenge as they are 
less amenable for treatment. As high grade tumours they  have short survival 
time,  and prognosis depends not only on tumour type  but  also  on   site  of  
the  tumour . 
 
 The major milieu of brain tumours are derived from glial cells called 
gliomas. Highly malignant tumours are glioblastomas. In past decade  in 
elderly people incidence of glioblastoma has increased  spuriously due to 
advances in neuroimaging  as even, the smaller lesions are picked out which 
were  missed  in  earlier  days. Hence according to Kurland and Schonberg(1) 
there is an ultimate  necessity for a descriptive data on primary brain tumours. 
hence this study  is designed to get a descriptive data. 
 
 Nervous system neoplasms affects both adults and children. The effects 
of these tumours were devastating even though they constitute a small 
percentage of all cancers. (2) Tumours of the CNS account for less than 2% of 
all malignancies (About 175,000 cases per year worldwide) (3) .The incidence 
does not vary markedly between regions or populations (Stewart and Kleihues, 
2003).  
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 Glial tumours are a varied   group of neoplasms. CD117 is a 
protooncogene encoded tyrosine kinase receptor. . It is expressed usually in 
some normal tissues and. It is also expressed in neoplasms like GIST. 
(gastrointestinal stromal tumours). Treatment with inhibitors of  receptor for 
tyrosine kinase namely imatinib   is proved  successful  in cases  like 
gastrointestinal stromal tumour which are  CD117- positive Likewise   aim  of 
this study  is to study  the expression of CD117 in  tumours  of glial origin, to 
prove the marker  as  useful tool for diagnostic purpose and treatment. This 
study also includes analysis of CD117    expression in glial tumor subtypes and 
grades. 
  
 
AIMS  
AND  
OBJECTIVES 
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AIMS AND OBJECTIVES 
 
1) To study the expression of CD117 in  Glial tumours 
2) To correlate the percentage of expression of CD 117 with tumor type and 
grade. 
3) To study the CD117 expression in tumours of glial origin as a useful tool for  
diagnostic and therapeutic purpose.  
4) To study the age, sex, and site predeliction of different types of gliomas. 
  
 
REVIEW  
OF  
LITERATURE 
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REVIEW OF LITERATURE 
 
 The central nervous system consists of, neurons, glial cells, 
meningothelial cells and endothelial cells of the blood vessels. Neurons form 
major part of the cells.  The glial cells form supporting cells. They are divided 
into macro and microglia. Macroglia are composed of astrocytes, 
oligodendrocytes, and ependymal cells, derived from  neurectoderm. microglia 
are derived from bone marrow  and they are the   phagocytic system of the 
CNS. 
 
 Astrocyte is the glial cell found throughout the CNS. They are called so 
because of their star shaped appearance, caused by multipolar branching 
cytoplasmic processes which have cytoplasmic intermediate filaments, named 
as glial fibrillary acidic protein. They are the main cells responsible for repair 
and scar formation in brain. 
 
 Oligodendrocytes are responsible for myelination in central nervous 
system. Ependymal cells are cuboidal cells lining the ventricles of 
cerebrovascular system Microglia are phagocytic system of the CNS derived 
from mesoderm. They are the fixed  macrophage  system  respond  to  injury  
by proliferation, producing  rod  cells  and   nodules  of  microglia. 
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 Neoplasms of the CNS was first described by Gupta longati a scientist  
from  Russia  in  the  year  1873  .They   account  for 2% of  all cancers  world    
wide.  Annual incidence of CNS neoplasms ranges from 10-17/100,000 people 
for intracranial tumours and 1 to 2 /100000 people for intraspinal tumours. In 
children 70% of tumours occurs in posterior fossa and in adults most common 
in the cerebral hemisphere above the tentorium(4-9).  CNS tumours are divided   
into four broad categories namely    
(1) gliomas     
(2) neuronal neoplasms  
(3) neoplasms which are poorly differentiated,     
(4) and the last category meningiomas.. 
 
 Gliomas are derived from glial cells and are composed of    
astrocytomas,     oligodendrogliomas,     and    ependymomas.   Gliomas are 
classified histologically by WHO (10). But recent advances in brain tumor   
research are complemented with a list of biomarkers for molecular 
histopathology, Focus is also increasing on drugs against targeted therapy of   
tumour cell population.  
 
 Glial cells are derived from adult neural stem cells and glial progenitor 
cells.  They have been   proven to share some traits with gliomas as proposed 
by   Sanai, Alvarez-Buylla etal. 2005(11)). 
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 Human gliomas   and  glioma  derived  tumourspheres   express  stem 
cell related genes.(12). 
 
 Neural stem cells show high  resistance  for senescence  and  apoptosis, 
so   they  need  lesser mutation for  transforming into malignant when  
compared  to   well   differentiated   counterpart  which    require  
approximately four to seven mutation  as   postulated by   (Renan1993; Sanai, 
Alvarez-Buylla et al. 2005)(11,13). 
 
 Adult  human  SVZ  has proliferating  adult  neural stem cells(14)  The 
biggest germinal  areas  of  adult  brain  is  the  sub  ventricular  zone  of  
lateral  wall of left ventricle,(11,14,15,16)   .MRI  shows   a  group  of  
glioblastomas  that  are associated with SVZ ,which arise as typically 
multifocal  lesions  and  recur   at  sites significantly  remote to primary 
tumour( 17) .Interestingly showing that some  gliomas  originate  in  a  mutated 
stem cell which give rise to transformed progenitor cell that can go away from 
the germinal area and multiply vigorously  once  they  reach  an  amicable 
microenvironment. 
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EPIDEMIOLOGY OF NERVOUS SYSTEM TUMOURS: 
 In an analysis made in nation wide registry 2005 in korea studied 5,692 
patients WHO were diagnosed as primary brain neoplasms   in 2005. It was 
seen that CNS tumours occurred in a F:M ratio of 1.43:1. It was found that   
meningiomas were the most common tumours (31.2) %.Of all the gliomas 
30.7% was glioblastomas, and among the malignant  tumours of   CNS 19.3% 
were glioblastomas. The medulloblastoma and germ call tumours were the 
most common tumours below 19 years of age (18). This study showed the 
epidemiology in korea. 
 
 CBTRUS-The Central Brain Tumor Registry of the United States   
analysed   data  from 1990–1994 consisting  of  all  primary  CNS tumours  
from 11 state cancer registries, 20,765 case data was  analysed and showed in 
general that  the cns tumours  annual incidence   was  at  11.5 cases per 100,000 
person-years  
• in male patients the incidence was  (12.1 per 100,000 person-years)  
• in female  the incidence was  (11.0 per 100,000 person-years)(19) 
 
 This study was conducted by Surawicz et al .it had similar results as the 
study of arora et al in England, it also showed that whites are affected more 
than blacks. Brain cancer accounts for1.4% of all cancer deaths and 2.3% of all 
cancer related deaths (20) 
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 Another  study conducted   by   arora  et  al   in  53326  primary  brain  
tumours showed  that  overall  incidence  was  9.21  per  100000  person years 
(21)
. and the  peak age affected was 70 -79 years. This study also showed that 
malignant tumours were 5.64%, benign tumours were 60%.it also showed 
supratentorial tumours affected older age group and infratentorial affected 
younger age group. 
 
 Similar work by Porter et al also shows that incidence of CNS tumours 
in united states was 18.1/100,000  person years.(22) 
 
 In india CNS tumours account for less than 2% of all malignancies. 
 
 According to ICMR statistics from 1982-1983 to 2002-2003   was 
studied incidence in males: according to Chennai registry 2.53 to 4.14 
according to Delhi registry. Incidence in females according to Bhopal registry 
was 1.46  to 2.66 according to  Delhi registry(23). 
 
 In pediatric age CNS tumours account for  27%  according to SEER 
programme  and  national cancer registry(24)   
 
 According to study of Linabery et al of pediatric CNS tumours from 
1992-2004 incidence in children were found to be 158/1000,000 person years. 
It was higher incidence in boys 29.9 per 10000,000 person years than girls of 
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25.1 per 1000,000 person years (25),  during the period of 1992-2004 and found   
that  the  incidence of  CNS tumours in children was 158 per 1,000,000 person-
years. It was more common in boys than in girls (29.9 per 1,000,000 person-
years as opposed to 25.1 per 1,000,000 person-years) 
 
 According to jain et al study in India paediatric CNS  tumours show 
14.8% incidence of all tumours. 
 
EPIDEMIOLOGY OF GLIOMAS 
• Diffuse astocytomas accounts for   10- 15 % 0f all astrocytic brain tumours 
and has incidence of 1.4 new cases per million population an year.(26) It  
represents the largest group and most prevalent tumour in adult brain(27). 
Over all  population  based  survival times  of  diffuse  astrocytoma  is  5.6 
years.(28) 
 
• Pilocytic astroctoma are slow growing neoplasms constituting 5-6% Of  
gliomas( 29) . Follows  an  incidence rate of 0.37 per 100 persons per year 
and also commonest glioma of paediatric age group .These gliomas most 
commonly occur  in cerebellum accounting to 68%.(30)   
 
• Pleomorphic xanthoastrocytoma relatively uncommon astrocytic tumour 
accounts for less than 1% of astroctytic tumours.the clinicopathological 
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features of this tumour was first described in 1979 and so far 200 cases are 
reported.(31) 
 
• Anaplastic astrocytomas occur in 50-75% of recurrent tumours(32).It  is 
usually present at the age of 45-51 years and male:female ratio of 1.31  to 
1.6 :1(29,30)   
 
• Most common brain tumour  is glioblastoma multiforme constituting   
12–15% of the brain tumours  and about 60-75% of  all the astrocytic 
tumours.(30,33)andfollows incidence rates of 2.96 per 100000 population per 
year.(29,30,33).Glioblastomas  has  preference for  cerebral hemispheres in 
adults  but in neonatal and  pediatric age group brain stem is the most 
common site(34) 
 
• Gliosarcoma is a sarcomatous  phenotype  of glioblastoma  constitutes  2-8 
%  of  all  cases  of  glioblastomas.(35,36,37,38)  
 
• Gliomatosis cerebri - usually occurs in between 40 and 50 years of age, but 
also seen in neonates. Both sexes are affected equally but at an early age in 
males when compared to females.(39) . 
 
• Oligodendroglioma accounts for 2% - 4% of all primary CNS 
neoplasms.and 9.5% of adult gliomas .Age adjusted incidence rates are 0.27 
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to 0.37 /100000 person years(40,41). It also constitutes 71 to 79 % of WHO 
gradeII  neoplasmspeak incidence rate.occurs in 35-44 years.. 
 
• Anaplastic oligodendroglioma constitutes minority of oligodendroglioma 
and  form  less  than 5% of new malignant gliomas.(42).They also consist of  
1.2% of all primary brain tumours with an  annual incidence rates of 0.07 to 
0.18 per 100000 population have been reported(29,30)  
 
• oligoastrocytoma  comprise  35 % of all oligodendroglial neoplasms and 
20% of WHO  grade 2 tumours,with an incidence rate of 0.1/100000 person 
years ( 39,41,43), 
 
• Ependymomas constitutes 5.8 % OF gliomas 2.1% 0f all primary CNS 
neoplasms, It comprises  for 50–60% of spinal gliomas (44) i.n 
adults.frequency of progression to anaplastic ependymoma is less common 
than astrocytic neoplasms (45) 
 
• subependymomas  constitutes  8% of all ependymal tumou.rs (46,47). 
 
• myxopapillary ependymoma COMPRISES  9–13% of all 
ependymomas{46,47)  most commonly occurs in cauda equine region.with 
male preponderance .M: F ratio of 2’2:1. 
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CLINICAL FEATURES: 
• The clinical presentation of CNS neoplasms present corresponding to site 
and nature. They are epilepsy, focal neurological deficits, symptoms and 
signs due to raised intracranial pressure like headache,vomiting, clouding of 
consciousness, coma, papilloedema, and hydrocephalus. Signs and 
symptoms of brain tumours are usually nonspecific like headache, nausea, 
vomiting paresthesia, seizure, paraplegia or hemiplegia. visual disturbance 
or increased intracranial pressure. Signs specific to site are behavioural 
changes in frontal lobe lesions. most common lesions causing seizures are 
oligodendroglioma, anaplastic oligodendroglioma and gliosarcoma. 
Neoplasms causing raised intracranial pressure are ependymoma, anaplastic 
ependymoma, oligodendroglioma and glioblastoma multiforme. Neoplasms 
that present with hydrocephalus are posterior fossa neoplasms, central 
neurocytoma, chordoid glioma of third ventricle, subependymal giant cell 
astrocytoma,hypothalamic pilocytic astrocytoma and pineal gland 
neoplasms.(30, 39,48,49,50) 
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RISK FACTORS AND ETIOLOGICAL AGENTS 
1) Sex: 
Gliomas are more common in men than women with M:F ratio of 60:40. 
2) radiation: 
 There is a strong correlation with exposure to therapeutic ionizing 
radiation like  treatment of  tinea capitis with development of gliomas  
according to Bondy et al 1994 and hodges et al 1992(51,52,53). Electromagnetic 
fields can produce mutation which favours tumorigenesis and causes brain 
tumours.This was studied by Gurney and vanwijnagaarden 1999. 
 
 Mobile phones: It was thought that there was link between non ionizing 
radiation of mobile phones and gliomas but various studies conducted showed 
no clear association.(54,55), Interphone international case control study in 13 
countries in 2765 gliomas and 2409 meningiomas showed no association 
between mobile phone usage and brain tuours 
3) Low penetrance gene: 
 The  popularly called GWAS - as genomic wide association studies  has 
revealed many  especially  seven chromosomal regions , (TERT),  telom erase 
reverse transcriptase, 1 (RTEL 1),   in the regulator of telomerase  longation 
helicase 1 (RTEL 1), cyclin dependent kinase inhibitor 2A and 2B (CDKN2A-
CDKN2B), coiled-coil domain containing 26 (CCDC26),  EGFR genes, TP53 
and PHLDB1 gene (pleckstrin homology-like domain family B member 1) , is 
associated with a increased risk of  glioma (56,57,58) 
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4). Genetic s syndromes: 
 In Literature as per study of Bondy et al ,  it is observed that there is  
strong association of  gliomas in families having mentally retarded child. Also 
seen in first degree relatives and clustering of cases seen in some families.it 
showed association with hereditary syndromes like neurofibromatosis 
NF1,NF2,tuberous sclerosis TSC1,TSC2, LiFraumeni  syndrome, turcot 
syndrome (59-63).  In 2007 an international study called  Gliogene has started 
analysing  susceptibility loci  in  families with more than two gliomas.It is an 
international study, started in 2007 to workup on the susceptibility loci  in  the  
families  with  more  than  two  glioma.(63)   
 
5) Viruses and glioma 
 In literature viruses have seen to be associated with carcinogenesis  For  
example  HPV  is  associated  with  cervical cancer. EBV  is known   to cause  
burkitts  lymphoma, nasopharyngeal carcinoma  and Hodgkin lymphoma  
likewise  gliomas   have been associated with sv 40 –simian 40 virus, 
cytomegalovirus, john Cunningham virus and adenovirus(64-70)  
 
6) Occupational  hazards 
 Literature  shows increased  incidence  of  brain cancer  among  farmers 
in vineyards exposed to pesticides. Studies reveal strong association. There was  
also increased  incidence of gliomas in workers of petrochemical industries, 
fire fighting and embalmers but definitive etiological agents are under study. 
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The  by  products  in  rubber  industry, n-nitroso compound  also  found  in  
nitrate  containing  preservative  have  found to have association with gliomas 
is under study.(71)  
 
ROLE   OF NEUROIMAGING IN GLIOMAS 
 MRI, CT  SCAN  are  primary modalities of investigation in brain 
tumour, in  which  CT  is  very  useful  when  skull  bone  is  involved. 
 
 MRI holds good when soft tissue is involved. In case of gliomas brain  
tissue  with  white  matter  looks  expanded. Imaging  also gives information  
on  site,  edema, dural attachment , enhancing lesions  indicate  vascularity and  
subsequent  neoplastic  nature. 
 
Other recent techniques are 
PET, positron emission tomography, 
MRS-Magnetic resonance spectrophotometry. 
FLAIR-fluid attenuation inversion recovery scan.in MRI is done. 
 SPECT-single photon emission computerised tomography   scan and 
angiogram 
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INTRAOPERATIVE  ANALYSIS  OF  SURGICAL SPECIMENS AND 
TYPES. 
 A methodological approach to the diagnosis is important in pathology, 
Hence intraoperative examination  plays an important role in neuropathology. 
The surgeon needs information whether the lesion is non neoplastic, benign or 
malignant and the grade of the tumour for malignant lesions .This information 
helps them to plan on the extent of resection. 
 
 The types  of  intra operative consultation are 
1) frozen section, 
2) csf cell cytology 
3) crush or squash preparation 
4) imprint cytology, 
5) open biopsy 
6) stereotactic needle biopsy 
7) secondary  biopsy and  
8) last resection specimens. 
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MACROSCOPIC SPECIMEN INTERPRETATION AND 
PROCESSING: 
 The  specimen  should  be  resected  in  such  a  way  that, arachnoid, 
gray matter  and  white  matter  are  seen.  In  order to get such a specimen it 
should be  sectioned  perpendicular  to  the  meninges. On  gross  examination  
tumorous  lesions  are seen as solid areas which cannot be  differentiated as 
either gray or white matter. They are usually admixed with haemorrhage and 
necroses. Cyst with a  mural nodule is seen in pilocytic astrocytoma and  some 
other astrocytomas .Gelatinous  and  cystic  areas  are  seen in 
oligodendroglioma. 
 
GLIOMAS –AN OVERVIEW 
 Gliomas in general are infiltrating neoplasms, less amenable for 
complete surgical resection. WHO classifies them according to cellularity, 
mitoses, pleomorphism, necroses and endothelial proliferation. 
 
WHO grading of  gliomas are  
 GRADE  I - Pilocytic astrocytoma 
                                 Desmoplastic astrocytoma 
                                 Myxopapaillary ependymoma  
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 GRADE II    -  Diffuse infiltrating astrocytoma , 
    a) fibrillary astrocytoma 
b) Gemistocytic astrocytoma 
c)protoplasmic 
Mixed gliomas 
Pleomorphic xanthoastrocytoma 
Oligodendroglioma 
Ependymoma 
 GRADE III - Anaplastic astrocytoma 
  Anaplastic ependymoma 
  Anaplastic oligodendroglioma 
  Anaplastic  oligoastrocytoma 
 GRADE IV  - Glioblastoma multiforme 
    Giant cell glioblastoma  
  Gliosarcoma 
 
Pilocytic astrocytomas (WHO grade I) : 
 It is a different  type of astrocytoma which  lacks infiltration into 
surrounding tissues ,hence carry better outcome than other gliomas. It affects 
children, adolescence and sometimes early adulthood. The tumour has 
predilection for cerebellum, hypothalamus, anterior optic pathway and third 
ventricle.in cases of NF1 it is seen in basal ganglia, thalami, cerebral 
hemispheres or spinal cord. Bilaterality is seen in optic nerve gliomas and 
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cerebellar astrocytomas. MRI T1 and T2 images shows microcystic areas 
within solid components. Microscopically  it is a tumour exhibiting biphasic 
pattern. architecturally and cytologically  areas of   microcystic  and  fascicular  
pattern  are  seen. Fascicular pattern is seen as bipolar cytoplasmic processes 
which are delicate the cells appear spindle or oval embedded in a fibrillary 
matrix. The other pattern of microcystic areas appears as neoplastic cells 
suspended in pools of myxoid basophilic material. Also seen are Rosenthal  
fibres and eosinophilic granular bodies. 
 
DESMOPLASTIC INFANTILE ASTROCYTOMA 
 It is nothing but tumours having histomorphology similar desmoplastic 
infantile glioma but with astrocytic differentiation. With slight female 
preponderance.(M:F =0.8:1)(72).This  tumour invariably occurs in infancy.it is a 
special variant consisting the  family of  neuronal –glial neoplasms .The age 
group of the  tumour occurs inbetween  2 to 24  months. They are 
supratentorial occupying commonly, frontoparietal, combination of sites also 
seen.(73). CT shows hyperdense lesion with contrast enhancement. The 
diagnostic histopathological feature is abundant desmoplasia seen as deposition 
of dense stroma in  along with fibroblasts  and primitive  neuroepithelial  
components. These  tumours  have  a  favourable prognosis revealing that the 
primitive  elements are not anaplastic.(73). 
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Pleomorphic xanthoastrocytoma (WHO grade II) 
 This tumour comes under family of desmoplastic neoplasms and it 
affects   late childhood and young adults. It is seen to affect temporal lobes. It 
usually presents with epilepsy.Neuroimaging studies show cystic well 
demarcated contrast enhancing mural nodule. Grossly it occupies 
leptomeninges and subarachnoid space with invasion into brain parenchyma. 
Microscopically the cells exhibit marked pleomorphism, the cytoplasm has a 
ground glass appearance and filled withlipid vacuoles. Also seen are 
pericellular reticulin The cells are seen admixed with spindle-shaped cells in 
fascicular array, a few tumor giant cells and lymphoid infiltrates.  Eosinophilic 
granular bodies which are lysosomes containing autophagic debris may be 
seen. It exhibits a favourable prognosis. 
 
Diffusely infiltrating astrocytomas 
 They forms the largest group of astrocytic tumours and is the most 
prevalent brain tumours of the adults. These are unique in having an inherent 
tendency for biologic progression due to stepwise accumulation of specific 
genetic abnormalities(21). The diffusely infiltrating astrocytomas is subclassified  
according to cytology of the tumour cells as – fibrillary, gemistocytic, and  
protoplasmic, of which diffuse fibrillary astrocytoma is the commonest. They 
are predominantly supratentorial lesions affecting frontal and temporal cerebral 
lobes but can be located anywhere in the CNS. The spinalcord and brain stem 
are the other frequently affected sites, while cerebellum is least likely to be 
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involved.  A peak incidence occurs between 30 and 40 years of age. The main 
feature of this tumour is its feature of transforming into anaplastic. If the 
cytological component of DFA is composed of cells with plump cell body, 
abundant eosinophilic cytoplasm, nucleus displaced by the cytoplasm ,named 
as gemistocytes comprises 20% cells then the tumour is called gemistocytic 
astrocytoma. 
 
Diffuse fibrillary astrocytomas (WHO grade II)  : 
 The above group are the common primary neoplasms of the human 
CNS(26)familial syndromes associated cases are seen in type 1 
neurofibromatosis, Li–Fraumeni (germline TP53 gene mutation) syndrome, 
hereditary nonpolyposis colorectal carcinoma type 1 Turcot syndrome and  
multiple enchondromatosis syndromes known as Ollier or Maffucci disease.(26) 
Neuroimaging shows areas of hypodensity that are non-enhancing by contrast 
media which is employed to define foci of blood–brain barrier disruption. 
Presence of enhancement indicates anaplastic transformation. Gross appearance 
varies from barely visible lesions to large, gelatinous, soft, ill-defined gray-
white areas that cause blurring of the gray-white interface expanding white 
matter and the cortex .Histologically these are hypercellular as compared  to 
normal brain, ill-defined infiltrative, lesions centered in the white matter or 
rarely in the cerebral cortex. Neoplastic astrocytes are slightly enlarged, 
pleomorphic and has angular hyperchromatic cigar-shaped nucleus. Cytoplasm 
is scanty with asymmetrical cell processes .The cell are seen in matrix showing 
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loose fibrillary glia. 
 
Gemistocytic astrocytoma (WHO grade II) : 
 These are tumours composed of  > 20% of large plump tumor cells with 
globose glassy eosinophilic cytoplasm and eccentric nucleus called the 
gemistocytes.  
 
Protoplasmic astrocytomas (WHO grade II)  : 
 They affect cerebral cortex of children and young adults. They are 
superficially located tumours. ‘protoplasmic’ astrocytes principally reside in 
gray matter, rather than white matter . Histology reveals cytologically uniform 
cells with moderate eosinophilic cytoplasm. The cells are evenly dispersed in a 
matrix of short cytoplasmic fibrils (cobweb-like), myxoid material and 
microcysts. Nuclei are monomorphous, round or slightly oval, with minimal  
mitotic  activity. 
 
Anaplastic astrocytoma (WHO grade III) : 
 Anaplastic astrocytoma is seen in adults (mean age of 45 years), in 
children pontine lesions have been reported. On neuroimaging a hypodense 
lesion with contrast enhancement should raise suspicion of anaplastic 
astrocytoma. They have a higher cellularity with pleomorphic and 
hyperchromatic nucleus. The other nuclear alterations includes angulation, 
dense hyperchromasia, and considerable variation in contour and dimension. 
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Mitotic figures are readily seen as compared to low grade lesion. 
 
Glioblastoma (WHO grade IV) : 
 There are two types according to etiology of glioblastoma namely 
‘Primary’ and ‘secondary’ variants are recognized. Secondary glioblastomas 
affects younger individuals as compared to the primary variants.Mean ages of 
secondary  GBM is  approximately 40 years, and that of primary GBM is 55 
years. On neuroimaging shows a typical ring-enhancement is seen also  
showing abnormal vascularization, its also has a  tendency to undergo 
spontaneous necrosis in the centre . Gross inspection shows a relatively 
circumscribed,clearly demarcated lesion with  hemorrhagic discoloration and 
focal yellow softening caused  due to coagulative necrosis which gives the 
variegated appearance. Histologically, glioblastoma is charecterised by  
extreme variation in cell cytology so  named as   glioblastoma ‘multiforme’. 
Foci of differentiated elements may be seen with multinucleated bizarre tumor 
giant cells. The tumour cells can be spindle, rhabdoid, epithelioid, signet ring 
or rarely small cell. The last often dominates the histologic picture in case of 
recurrence, in such case the term small cell glioblastomas is used. The other 
known variants of GBM are giant cell glioblastoma, ‘glioblastoma with 
oligodendroglioma component’ ‘glioblastomas with primitive-neuroectodermal 
tumor-like components’. 
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GLIOSARCOMA 
 It is a combination of   gliomatous areas with sarcomatous region in 
varying proportions. The gliomatous area is astrocytic in nature with anaplasia. 
sometimes focal carcinomatous areas(74) J38 with gland formations or 
squamous metaplasia(75,76)  can be seen in the glial portions. The sarcomatous 
component often shows typical fibrosarcoma like areas, occasionally resembles 
malignant fibrous histiocytoma(77,78). A subset of cases may show other 
mesenchymal differentiation like areas of bone, cartilage, smooth and striated 
muscle ,osteoid-chondral tissue  rarely lipoma like area.(79-,82)   
 
Oligodendrogliomas 
 It is a another set of tumours included in gliomas. It includes classic and 
anaplastic type.  
 
 Oligodendroglioma, WHO grade II:  
 It affects young and middle-aged adults involving the cerebral 
hemispheres (the temporal and frontal lobes). It is the well-differentiated mor 
that exhibits little mitotic activity and is devoid of proliferative microvascular 
alterations or necrosis. Nodular foci of increased cellularity alone are 
compatible with this diagnosis Neuroradiologic study shows partial 
calcification diagnostic of oligodendroglioma. Oligodendrogliomas  primarily 
involves the white matter with infiltration into the overlying cortex. It is 
composed of soft, gelatinous, gray–pink tissue, with cystic change also 
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contains a foci of dense calcification the cells are uniform, nuclei are round and  
an artefactual dissolution of cytoplasm accounts for the fried egg appearance. 
 
  These cells are seen in sheet-like arrangements.  Scattered 
calcospherites, may be seen along the advancing edge of the tumor, and with 
‘chicken wire’ like thin-walled blood vessels, also seen are  'satellitosis’- which 
is explained as  perineuronal tumor cell aggregation can be seen 
 
Anaplastic oligodendroglioma, (WHO grade III) 
 It may evolve in an already - existing  oligodendroglial neoplasm of 
low-grade character or develop  de novo. Dense cellularity, nuclear atypia, 
microvascular proliferation, endothelial hypertrophy and increased mitotic 
activity – with necrosis is characteristic of these tumours.. Tumour has avery 
bad prognosis  
 
Ependymal tumours 
 The gliomas include tumours from ependymal cells, called 
ependymoma, which in turn possesses unique characteristics. 
 
 Ependymomas 
 Ependymomas   has age with site predeliction, intracranial lesions are 
seen in  childhood and itramedullary lesions  are seen in  adults.it also 
comprises 6-9% of primary CNS neoplasms. In the fourth decade 66 % is seen 
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in the fourth ventricle, and hence it causes obstructive hydrocephalus.in MRI 
they are contrast enhancing lesions that are well circumscribed. These lesions 
are found arising from floor of the fourth ventricle. 
 
 Ependymomas originating in spinal cord commonly arises from the 
cervicothoracic segments. except myxopapillary type. They constitute the 
position of being the commonest of all neoplasms in adult(83,84).In cases of 
ependymomas  seen  in  cases of  neurofibromatoses -2 (NF-2), characteristic 
features are  multifocality   and   intramedullary location(83). They have also 
seen to arise from   cranial nerves(85), retina(86), and the sella turcica(87) . 
 
 Microscopically, the perivascular pseudorosettes are  seen as dense 
meshwork of fibrillary cytoplasmic process of ependymal cells which condense 
around blood vessels. True rosettes are tubules resembling normal 
ependymocytes can be seen cells have nuclei which are spindly having uniform 
granular chromatin without nucleoli. Some cells show cytoplasmic  
pseudoinclusions(88). Also lesions which have dense celluarity, narrow 
pseudorosettes and occasional mitosis are called cellular ependymoma. 
Dystrophic calcification is sometimes present. Literature also describes variants 
like giant cell xanthomatous and melanotic ependymomas.  
 
 Tanycytic ependymomas   are a variant  of  ependymomas  in  which.  
tanyos is a greek word meaning to stretch.as the name implies  these  are  
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tumours  which have fascicular growth  pattern  and also seen are,spindly 
cytology admixed with  illformed  pseudorosettes   predominantly  seen in 
spinal levels .(89) . 
 
 Clear cell ependymomas(90 91) are seen especially in  supratentorium  
showing  clear cell morphology  with  calcospherules  along  with  rich 
vascularity. Also seen are brisk mitotic activity. The cells show nuclear  
features of  high grade. 
 
 Another variety of  ependymomas  have  papillary  processes  lined  by 
neoplastic columnar epithelial cells  and  is  so called papillary ependymomas 
 
Anaplastic ependymoma - grade III WHO 
 These are a group of poorly differentiated tumours having dense 
cellularity, brisk mitotic activity necrosis, and also seen are pseudopalisading 
and rich microvascular proliferation). As the name suggest they are highly  
aggressive tumours with short survival.  
 
Myxopapillary ependymoma  grade I WHO 
 It is seen most commonly in the conus medullaris(92). They are mostly 
seen as extradural ependymomas in the region of sacrococcyx in the 
subcutaneous tissues(93,94) or,  sometimes extremely rare in the sacrum. rarely 
(95)
 The common age group of these tumours are third to fifth decades  of  ones, 
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life. Neuroimaging studies usually shows a contrast-enhancing sharply well 
circumscribed  mass. Microscopically the tumour cells seem to be cuboidal and 
are also seen are mucinous basophilic material which are seen to surround   
blood vessels. 
 
Subependymoma  grade I –WHO 
 It mainly affects adults and common site involved are the fourth 
ventricles, lateral ventricle, cerebral aqueduct. It can also be seen in third 
ventricle, or spinal cord (96,97,98). 
 
 Subependymomas are seen to be well lobulated and delimited lesions.  
While Small ones are solid lesions larger lesion are cystic. Calcification is seen 
most commonly. Histo pathology shows three features they are tumor cells 
arranged in multinodular pattern seen in aggregates, dispersed in a voluminous 
fibrillary matrix in a disorganized manner, also seen are compact or 
microcystic areas. Tumor cell nuclei are oval in shape consisting of punctate 
chromatin. 
 
Mixed gliomas 
 These are  infiltrative lesions affecting  the cerebral hemispheres  of 
adults especially the frontal and temporal lobes and are termed  as  
oligoastrocytomas  comes  under WHO grade II and  anaplastic 
oligoastrocytomas  comes under WHO grade III. Anaplastic astrocytoma has   
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higher cellularity, nuclear atypia, readily apparent mitotic activity and complex 
microvascular hyperplasia rarely. 
 
Prognostic factors in Glial tumours: 
1) The age of the patient(99)  
2) Karnofsky Performance Status at the time of diagnosis(100) ,  
3) Extent of surgery(101)   
4) Macroscopically radical resection (102),  
5) Another prognostic factor is a histological grade and type are known to 
affect prognosis. 
 
 Glioblastoma patients with promoter region methylation of  MGMT 
gene are treated with Temozolomide(103,104)  and those treated with 
Bevacizumab(105) have an    increased   chance  of  prolonged  disease  free  
survival . 
 
CYTOGENETICS: 
 It was initially thought glioblastoma arise in two different settings 
clinically one in elderly, called primary and another seen less commonly in 
younger age groups .as transformation of low grade tumours to high grade 
ones. Advances in molecular genetics (Data From Cancer Genome Atlas 
Network) have classified  glioblastomas under four categories namely classic 
type  showed PTEN mutation EGFR gene amplification and also, chromosome 
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10 deletion., also seen are focal deletions of chr 9p21. mesenchymal type seen 
are deletions of  the NF1gene on chr 17, also highly expressed  are  NF-KB  
pathway  genes, and  TNF   pathway  genes. Neural type shows increased 
neuronal marker expression namely, NEFL, GABRA1, additional markers 
expressed are SYT1 and SLC12A5.  
 
 Proneural Type is most commonly seen in secondary glioblastomas is  
associated with  TP53 mutation and point mutation of IDH1 and IDH  
2 gene. They also show over expression of  PDGFRA. Low grade gliomas  
have  mutations in TP53 and also IDH genes.R tumours. 
 
• Cytogenetic studies  in  pilocytic astrocytomas  show normal karyotype 
in majority of cases.(106,107,108),  but  studies show  have  postulated some     
balanced translocations {108}.or minute copy number changes. 
• Pleomorphic xanthoastrocytoma also discovered to have gain of 
chromosomes 7 and 3 frequently.(109,110,111). Most of them are diploid.  
(112,113)
. 
• Low-gradeastrocytoma which possess TP53 mutation show very less 
time for progreession into diffuse astrocytoma   {114, 115}. 
• TP 53 mutations are also seen in higher frequency in anaplastic 
astrocytoma. (116, 117, 118, ) . Other mutations seen are 35-60% of  LOH 10q 
mutations,18 -23 % of PTEN mutations. {119,120,121, 122, }   
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• Gliosarcoma possess  the following mutations  (123,124,125,),   
PTEN mutations   -   (38–45%) 
p16INK4a deletions  -   (38%) 
TP53 mutations   -  (23–24%), 
 
 Oligodendrogliomasis  both classical and anaplastic variety  seems to   
possse  unbalanced translocation in  chromosomes 1 and 19 [t(1;19) (q10;p10)], 
lesser expression is seen in  anaplastic astrocytoma.(125) 
 
 Ependymomas, show aberrations involving  chromosome 22 very often. 
{126}   like deletions Monosomy  or translocations . 
 
ROLE OF IMMUNOHISTOCHEMISTRY IN NERVOUS 
SYSTEM TUMOURS: 
 The armamentarium of Diagnostic neuropathology has improved more 
in recent past due to immunohistochemistry techniques in addition to squash 
and histomorphology. New reagents are being developed against specific 
antigens associated with stages of cell lineage, oncogene, cell cycle and  
suppressor gene product or cell activation. Use of these antibodies will    help 
us to define the nature of cellular maturation, tissue differentiation, tumour 
progression, and metastasis. 
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 It is of great help in cases of metastases with unknown primary as the 
metastases express antibody of parent site Immunohistochemistry helps us not 
only to know about the cell of origin ,ability of the tissue to express a particular 
antigen but also its exact cellular localization. This method also employs  
antibodies to distinguish the antigenic differences between the cells.  These 
antigens can identify cellular lineage,within particular cell lineage different 
subsets,and also some infections. 
 
 For immunohistochemistry, Peroxidase – antiperoxidase method, 
Avidin-biotin method are commonly used methods. The important step is 
selection of antibody particular that antigen. 
 
 The most important groups of antibodies are  Intermediate filaments, 
Neuroendocrine related proteins, Markers with predominant expression in CNS 
tumour, Markers associated with suppressor genes, oncogenes and related gene 
products,. Markers to detect cell proliferation and cell death in CNS tumours 
 
Immunohistochemical markers most widely used are; 
1) Keratin - identifies epithelium 
2) Vimentin – identifies Mesenchymal cells, Astrocytes, 
3) Glial fibrillary acidic protein (GFAP) identifies. glial cells 
Astrocytes. Nonmyelinating Schwann cells, Ependymal cells 
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ROLE OF CD117 IN GLIAL TUMOURS 
 CD 117 is a proto-oncogene, a C KIT product, tyrosine kinase receptor, 
found to be located in chromosome 4 in its long arm.  This receptor has many 
specialised unique biological functions. The expression of this receptor is seen 
in some tumours and also few normal cells.  CD117 expression  has  found its         
place in immune histochemistry  after the  successful  treatment  of  CD117     
positive  gastrointestinal stromal tumours  being treated with tyrosine kinase      
inhibitors, namely Imatinib. Hence in this concept the evaluation of CD117      
distribution and its functions, the evaluation of this receptor, its encoding gene 
in many tumours of central nervous system is very useful. As  the fact is only    
that very little data is  available  on immunohistochemical expression of CD117 
in glial tumours, this study is aimed at  determining  CD117 expression in these  
tumours  in all grades   and all histopathological types .It also  correlates and 
compares the percentage of stained cells and  intensity of staining in different 
pathological grades . It also analyses the uniqueness in immunoreactivity in 
various histopathological type and grades. 
 
 According to the study of Parvin et al(127). However, the intensity of 
CD117 expression as well as the percentage of stained cells shows difference 
of considerable significance among low-grade tumours and high- grade 
gliomas, suggesting them as helpful parameters in making distinction between 
the low-grade and high-grade gliomas when determination of grade is not 
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straight forward. Study of parvin et al shows that high grade gliomas showing 
prominent expression of CD117 can be subjected to chemotherapy with 
tyrosine kinase inhibitors. 
 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
 This is a retrospective descriptive clinicopathological analysis of  
gliomas in the Department of Neuropathology, Madras Medical College and 
Rajiv Gandhi Government General hospital, Chennai during the period of jan  
2013 to dec 2014  
 
Source of data: 
            Cases of gliomas  reported in the Department of Neuropathology, 
Madras Medical College during the period of jan 2013 to dec  2014 from the 
Department of Neurosurgery, Rajiv Gandhi Government General hospital. A 
total 836 specimens where received during this study period, out of this 263 
cases are gliomas. 
 
Inclusion Criteria: 
 Patients diagnosed as  glial  tumours  astrocytoma,  oligod endro glioma, 
oligoastrocytoma,  ependymoma, their subtypes and combinations. As per the 
WHO grading system, tumours of glial origin are grouped  as either low or 
high grade. WHO Grade I and II are considered as low grade tumours and 
WHO grade III and IV are considered as tumours of high grade. 
 
Exclusion criteria: 
 Nonneoplastic lesions  of  CNS,  benign lesions of  CNS, meningiomas,  
lymphoid neoplasms and  all  other neoplasms excluding gliomas. 
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METHOD OF DATA COLLECTION: 
 This is a retrospective study. Relevant clinical details regarding age, sex, 
symptoms, radiological findings including CT and MRI, per operative squash 
findings and gross findings were obtained for all the case of glioma from 
neuropathology registers from january 2013 to December 2014. and relevant  
investigations are collected from the medical records of Institute of pathology, 
Madras Medical College, Chennai between the period of 2013-2014. Out of 
these cases a total of 50 cases which were representative of the Whole sample 
was selected randomly with grade-I(9 cases), grade II(15 cases), grade III 
(7cases), grade IV (19 cases). 
 Corresponding paraffin blocks are collected and histopathological 
sections are prepared in a glass slide   from formalin fixed paraffin embedded 
tissue of resected specimens. They are subjected to H&E staining and 
immunohistochemical analysis by primary marker CD117. This is done for a 
total of 50 selected cases. The results were tabulated in a master chart and also 
recorded with photographs. As far as possible follow up data   regarding 
adjuvant therapy, recurrence disease free survival, for some patients were got 
from MRD –medical records section Follow up data of some of the patients 
regarding the adjuvant therapy, recurrence, disease free survival were obtained 
from Medical Records Section of Department of neurosurgery and oncology. 
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IMMUNOHISTOCHEMICAL EVALUATION: 
 Immuno Histochemistry is a molecular technique which was first 
described by Dr.Albert Coons in 1941. Immunohistochemical analysis using 
CD 117 were done in paraffin embedded tissue samples using poly Excel 
detection system protocol. Due to economic constraints, immunohistochemistry   
were done only for 50 cases. 4 micron thickness of paraffin embedded sections 
are taken and transferred to gelatin coated slides. Antigen retrieval is done 
using EDTA buffer, as antigen retrieval solution. And heat retrieval 
methodology is used for antigen retrieval.   
 
 Sections with a thickness of 4 µ from selected formalin fixed paraffin 
embedded tissue samples were transferred onto gelatin coated slides. Heat 
induced antigen retrieval was done. The antigen is bound with rabbit  
monoclonal antibody (Pathnsitu) CD117 receptor and then detected by the 
addition of secondary antibody  conjugated with horse radish Peroxidase-
polymer and Diaminobenzidine substrate. 
 
ANTIBODIES IN IMMUNOHISTOCHEMISTRY 
Antigen Vendor Clone Species Dilution Positivity 
Positive   
control 
CD117-C-
terminus 
Pathn  
Situ EP10 
Rabbit – 
igG 
1:50  
To 
1:100 
Cytoplasm 
&membrane 
Gastrointestinal  
stromal  
tumour 
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INTERPRETATION & SCORING SYSTEM: 
 The immunohistochemically stained slides were analyzed under the 
microscope for the presence of reaction which was detected by the brown 
colour of DAB chromogen and various parameters are analysed namely 
1) Cellular localization - both  cytoplasmic and  membrane positivity 
2) Among the neoplastic cells the percentage of cells stained. IHC stained cells 
was graded by a semiquantutative scale which ranges from 
 score 0   - No immunoreactive cells 
 score 1+ - 1-10% 
 score 2+  - 11-50% 
 score3+  - 51-75% 
 score4+  - more than 75% (128) 
3) The intensity of staining reaction was graded as Weak, moderate and  
strong. 
 
STATISTICAL ANALYSIS: 
 The statistical analysis is   performed using statistical package for social 
science software version IBM SPSS 20. For analysis for category variables we 
have used CHI SQUARE test 
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AND  
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OBSERVATION AND RESULTS 
 
 The total number of cases received in our institute of neuropathology 
were 836 cases over a period of 2 years, from jan 2013 to dec 2014. Out of 
which 274 were non neoplastic, 562 were neoplastic. Among the neoplastic 
cases, 263 cases were gliomas, 137 cases were meningiomas  and rest 299 were 
other neoplasms like, tumour of sellar origin, neurectodermal tumours, germ 
cell neoplasms etc. 
 
TABLE 1: Distribution of cases in neuropathology department 
 
Gliomas constitute maximum incidence of 31.4% among all cases. 
 No of cases Percentage 
Non neoplastic 274 32.8 
Gliomas 263 31.4 
Meningiomas 137 16.4 
Other neoplasms 162 19.4 
Total 836 100 
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CHART   NO 1 : INCIDENCE OF GLIOMAS 
 
 The age distribution of gliomas has been tabulated among the 263 cases. 
In this study, the minimum age in which glioma was observed was 6 months. 
The maximum age observed was 85 and it showed a mean age of 38 years with 
a standard deviation of 19.6.  
 
DISTRIBUTION OF AGE IN THE STUDY 
 N Minimum Maximum Mean 
Std. 
Deviation 
AGE 263 0.5years 85 37.9224 19.67214 
 
 
 
31%
69%
Gliomas
others
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23%
30%
37%
8%
2%
AGE WISE DISTRIBUTION OF GLIOMAS
upto 20 years
21-40 years
41-60 Years
61-80 years
above 80 years
TABLE NO 2  : AGE  WISE DISTRIBUTION OF GLIOMAS 
Age_group No of cases Percent 
upto 20 years 60 22.8 
21-40 years 79 30.0 
41-60 Years 98 37.3 
61-80 years 22 8.4 
above 80 years 4 1.5 
Total 263 100.0 
 
 
CHART NO 2 : AGE  WISE DISTRIBUTION OF GLIOMAS 
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The above table shows there is no specific increase in incidence of 
gliomas with increasing age. 
 The  peak  incidence  of    gliomas  was  seen  in  41-60  years  
accounting to 98 cases(  37.3 %) .  
 It also shows  least incidence of gliomas  in the  age group  more than  
80 years accounting to 4  cases.(1.5%). 
TABLE 3  DISTRIBUTION OF  HISTOLOGICAL SUBTYPES OF  
GLIOMAS 
 HISTOLOGICAL SUBTYPE NO OF 
CASES 
Percentage 
1)  PILOCYTIC ASTROCYTOMA 38 14.4 
2)  MYXOPAPILLARY EPENDYMOMA 2 .8 
3)  DESMOPLASTIC ASTROCYTOMA 1 .4 
4)  GEMISTOCYTIC ASTROCYTOMA 1 .4 
5)  DIFFUSE      FIBRILLARY    18 6.8 
6)  DIFFUSE  ASTROCYTOMA 20 7.6 
7)  PLEOMORPHIC    3 1.1 
8)  OLIGO ASTROCYTOMA 5 1.9 
9)  OLIGODENDROGLIOMA 20 7.6 
10) GANGLIOGLIOMA 6 2.3 
11) EPENDYMOMA 24 9.1 
12) ANAPLASTIC ASTROCYTOMA 21 8.0 
13) ANAPLASTIC  OLIGO 2 .8 
14) ANAPLASTIC  2 .8 
15) ANAPLASTIC  EPENDYMOMA 6 2.3 
16) GLIOBLASTOMA MULTIFORME 94 35.7 
Total 263 100.0 
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 From the above table it is inferred that out of the 263 gliomas studied in 
a two year period in our institute Glioblastoma multiforme was the most 
common one accounting for 94 cases (35.7%). Pilocytic astrocytoma was the 
second most common glioma accounting for 38 cases (14.4%).  
 Least common were pleomorphic xanthoastrocytoma (1.1%), 
oliogoastrocytoma (1.9%), anaplasticoliogoastrocytoma (0.8%), Anaplastic 
oligodendroglioma (0.8)%.  
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TABLE 4  :  SEX DISTRIBUTION OF GLIOMAS 
SEX NO OF CASES PERCENTAGE 
Male 168 63.9 
Female 95 36.1 
Total 263 100.0 
  
 The above table shows that gliomas have a male preponderance.  Out of 
the 263 cases studied 63.9 % (168) of cases have occurred in males and 36.1 % 
(95) of cases have occurred in females. 
 
 
CHART  4 : SEX DISTRIBUTION OF GLIOMAS  
 
 
Male
Female
45 
 
 
TABLE 5 : DISTRIBUTION OF SIDE INVOLVEMENT  OF BRAIN  IN 
GLIOMAS 
SIDE NO OF CASES PERCENTAGE 
LEFT 87 33.07% 
RIGHT 118 44.8% 
MIDLINE 58 22.05% 
TOTAL 263 100% 
 
 In the above table right side of brain was most commonly involved 
44.8%, left side 33.07%, and other midline deep structures 22.05%. 
 
CHART NO 5 : DISTRIBUTION OF SIDE INVOLVEMENT   
OF BRAIN  IN GLIOMAS 
 
33%
45%
22%
LEFT
RIGHT
MIDLINE 
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TABLE 6 : SITE WISE  DISTRIBUTION  OF GLIOMAS 
 SITE NO OF 
CASES 
Percentage 
1.  FRONTAL 52 19.8 
2.  FRONTOPARIETAL 23 8.7 
3.  FRONTO TEMPORAL 13 4.9 
4.  TEMPORAL 30 11.4 
5.  TEMPOROPARIETAL 34 12.9 
6.  PARIETAL 17 6.5 
7.  OCCIPITAL 12 4.6 
8.  PARIETOFRONTAL 2 .8 
9.  CEREBELLUM. 7 2.7 
10.  CPANGLE. 2 .8 
11.  BRAIN STEM, 5 1.9 
12.  CORPUS CALLOSUM 7 2.7 
13.  INTRAVENTRICULAR 14 5.3 
14.  POSTERIOR FOSSA 19 7.2 
15.  OPTIC NERVE 1 .4 
16.  OPTIC CHIASMA 1 .4 
17.  BASAL GANGLIA 7 2.7 
18.  SUPRASELLAR 3 1.1 
19.  ED SOL 1 .4 
20.  ID IM SOL 10 3.8 
21.  ID EM 3 1.1 
 Total 263 100.0 
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 The cerebral lobes are most commonly involved by glioma of which 
frontal lobe has the highest incidence accounting to 19.8 %( 52 cases). The 
second most common is the temporoparietal region accounting to 12.9 % (34 
cases). The occipital lobe showed the least common involvement accounting to 
4.6% (12 cases). 
 In the spinal cord out of the 14 cases,  intradural intramedullary  lesions 
were most common accounting to 10 cases (3.8% 0f total cases), intradural 
extra medullary was second most common accounting to  3 cases (1.1% of total 
cases) and one case was extradural lesions accounted to 0.4% of total cases. 
 
CHART NO 6 : SITE WISE  DISTRIBUTION  OF GLIOMAS 
 
 
 
 
19.8%
8.7%
4.9%
11.4%
12.9%
6.5%
4.6%
0.8%
2.7%
0.8%
1.9%
2.7%
5.3%
7.2%
0.4%0.4%
2.7%
1.1%0.4%
3.8%
1.1%
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
F
R
O
N
T
A
L
F
R
O
N
T
O
P
A
R
IE
T
A
L
F
R
O
N
T
O
 T
E
M
P
O
R
A
L
T
E
M
P
O
R
A
L
T
E
M
P
O
R
O
P
A
R
IE
T
A
L
P
A
R
IE
T
A
L
P
A
R
IE
T
O
O
C
C
IP
IT
A
L
P
A
R
IE
T
O
F
R
O
N
T
A
L
C
E
R
E
B
E
L
L
U
M
.
C
P
A
N
G
L
E
.
B
R
A
IN
 S
T
E
M
,
C
O
R
P
U
S
 C
A
L
L
O
S
U
M
IN
T
R
A
V
E
N
T
R
IC
U
L
A
R
P
O
S
T
E
R
IO
R
 F
O
S
S
A
O
P
T
IC
 N
E
R
V
E
O
P
T
IC
 C
H
IA
S
M
A
B
A
S
A
L
 G
A
N
G
L
IA
S
U
P
R
A
S
E
L
L
A
R
E
D
 S
O
L
IM
 S
O
L
ID
 E
M
48 
 
TABLE 7: DISTRIBUTION OF GLIOMAS- GRADEWISE 
 
CHART NO 7 : DISTRIBUTION OF GLIOMAS  GRADEWISE 
 
 All the  263  cases  of  gliomas, were  grouped  according  to  WHO 
classification  into four grades  namely  grade I - IV. WHO Grade I and II are 
grouped together as low grade and Grade III and IV are grouped under high 
grade in this study.  
 
 No of cases Percentage 
WHO     
GRADE 
I 40 15.2 
II 97 36.9 
III 33 12.5 
IV 93 35.4 
Total 263 100.0 
15%
37%
13%
35%
I
II
III
IV
49 
 
 In the above table 40 cases belong to grade I, 97 cases belong to grade 
II, 33cases belong to grade III, and 93 cases belong to grade IV, constituting 
15.2%, 36.9%, 12.5%, 35.4% respectively. 
 It was found that most common grade was WHO grade II tumours      
(36.9 %), followed WHO grade IV tumours (35.4%). 
TABLE NO 8 : CORRELATION OF AGE AND GRADE OF GLIOMAS. 
 
P<0.001* 
 
 The   above  table  is  given  to  analyse  if  there  is  any  particular  age 
predilection  for different grades of  tumour. 
 
 
WHO   GRADE 
Total 
I II III IV 
Age 
Group 
upto 
20 
years 
Count 32 22 4 2 60 
% 53.3% 36.7% 6.7% 3.3% 100.0% 
21-40 
years 
Count 6 40 16 17 79 
% 7.6% 50.6% 20.3% 21.5% 100.0% 
41-60 
Years 
Count 2 30 10 56 98 
% 2.0% 30.6% 10.2% 57.1% 100.0% 
61-80 
years 
Count 0 5 2 15 22 
% 0.0% 22.7% 9.1% 68.2% 100.0% 
above 
80 
years 
Count 0 0 1 3 4 
% 0.0% 0.0% 25.0% 75.0% 100.0% 
Total 
Count 40 97 33 93 263 
% 15.2% 36.9% 12.5% 35.4% 100.0% 
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 WHO grade I tumour was most common in age group of less than 20 
year, (53.3%). WHO grade II was most commonly seen in age group of 21-40 
years (50.6 %). WHO grade IV tumours are commonly seen in the age group 
above 80 years (75% ). 
 
CHART NO 8 : CORRELATION OF AGE GROUP WITH  
GRADE OF GLIOMAS 
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TABLE NO 9 : CORRELATION OF  SUBTYPES OF GLIOMAS WITH AGE 
 This table shows various percentage of different types of tumours, in different  age  group. it also show in which age group the 
particular tumor predominantly affects. 
DIAGNOSIS * age_group  correlation 
 
age_group 
Total upto 20 
years 
21-40 
years 
41-60 
Years 
61-80 
years 
above 80 
years 
 
PILOCYTIC ASTROCYTOMA Count 32 4 2 0 0 38 % 84.2% 10.5% 5.3% 0.0% 0.0% 100.0% 
MYXOPAPILLARY 
EPENDYMOMA 
Count 0 2 0 0 0 2 
% 0.0% 100.0% 0.0% 0.0% 0.0% 100.0% 
DESMOPLASTIC 
ASTROCYTOMA 
Count 1 0 0 0 0 1 
% 100.0% 0.0% 0.0% 0.0% 0.0% 100.0% 
GEMISTOCYTIC 
ASTROCYTOMA 
Count 0 1 0 0 0 1 
% 0.0% 100.0% 0.0% 0.0% 0.0% 100.0% 
DIFFUSE  FIBRILLARY 
ASTROCYTOMA 
Count 1 12 5 0 0 18 
% 5.6% 66.7% 27.8% 0.0% 0.0% 100.0% 
DIFFUSE  ASTROCYTOMA Count 1 8 8 3 0 20 % 5.0% 40.0% 40.0% 15.0% 0.0% 100.0% 
PLEOMORPHIC 
XANTHOASTROCYTOMA 
Count 1 0 2 0 0 3 
% 33.3% 0.0% 66.7% 0.0% 0.0% 100.0% 
OLIGO ASTROCYTOMA Count 0 2 3 0 0 5 % 0.0% 40.0% 60.0% 0.0% 0.0% 100.0% 
OLIGODENDROGLIOMA Count 0 9 10 1 0 20 % 0.0% 45.0% 50.0% 5.0% 0.0% 100.0% 
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GANGLIOGLIOMA Count 3 3 0 0 0 6 % 50.0% 50.0% 0.0% 0.0% 0.0% 100.0% 
EPENDYMOMA Count 15 7 2 0 0 24 % 62.5% 29.2% 8.3% 0.0% 0.0% 100.0% 
ANAPLASTIC 
ASTROCYTOMA 
Count 0 12 7 1 1 21 
% 0.0% 57.1% 33.3% 4.8% 4.8% 100.0% 
ANAPLASTIC  OLIGO 
ASTROCYTOMA 
Count 1 0 0 1 0 2 
% 50.0% 0.0% 0.0% 50.0% 0.0% 100.0% 
ANAPLASTIC    
OLIGODENDROGLIOMA 
Count 0 0 1 1 0 2 
% 0.0% 0.0% 50.0% 50.0% 0.0% 100.0% 
ANAPLASTIC  
EPENDYMOMA 
Count 3 2 1 0 0 6 
% 50.0% 33.3% 16.7% 0.0% 0.0% 100.0% 
GLIOBLASTOMA 
MULTIFORME 
Count 2 17 57 15 3 94 
% 2.1% 18.1% 60.6% 16.0% 3.2% 100.0% 
Total 
Count 60 79 98 22 4 263 
% 22.8% 30.0% 37.3% 8.4% 1.5% 100.0% 
 
P<0.001* 
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The commonest age group of individual tumour has been inferred from 
the table. Pilocytic astrocytoma was found to commonly affect the age group of 
0 to 20 years.  Myxopapillary ependymoma was found commonly to affect the 
age group of 20- 40 years  
 Diffuse fibrillary astrocytoma was found commonly to affect the age 
group of 21-40 years. 
 In Diffuse astrocytoma, out of the 22 cases studied 8 cases occurred in 
21-40 years and 8 cases occurred in 41-60 years. 
 Pleomorphic xanthoastrocytoma -three cases were studied two cases 
occurred in 41-60 years. 
 Anaplastic astrocytoma - out of the 21 cases, 12 cases occurred in 21-40 
years age group and in 7 cases occurred in  41-60 years age group. 
 Glioblastoma multiforme- out of the 94 cases studied 57 cases (60.6%) 
occurred in an age group of 41-60 years. 
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TABLE NO 10 : CORRELATION OF AGE GROUP  
WITH SEX  OF GLIOMAS 
Age group 
SEX 
Total 
Male Female 
upto 20 years 
Count 32 28 60 
% 19.0% 29.5% 22.8% 
21-40 years 
Count 53 26 79 
% 31.5% 27.4% 30.0% 
41-60 Years 
Count 65 33 98 
% 38.7% 34.7% 37.3% 
61-80 years 
Count 14 8 22 
% 8.3% 8.4% 8.4% 
above 80 
years 
Count 4 0 4 
% 2.4% 0.0% 1.5% 
Total 
Count 168 95 263 
% 100.0% 100.0% 100.0% 
 
P=0.218 
 
 In the above table, at all age groups males are most commonly affected 
than females. 
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CHART NO 10 : CORRELATION OF AGE GROUP  
WITH SEX  OF GLIOMAS 
 
 
 
TABLE 10 A : MEDIAN AGE AT DIAGNOSIS 
 
AGE 
Count Mean Maximum Minimum Median 
SEX 
Male 168 39.35 85.00 .60 40.00 
Female 95 35.39 78.00 2.00 37.00 
 
 The median age at diagnosis in males was 40 years,and in females was 
37 years . 
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TABLE 11 CORRELATION OF SEX WITH   
GRADE OF GLIOMA 
  
GRADE 
Total 
I II III IV 
SEX 
Male 
Count 25 62 21 60 168 
% 14.9% 36.9% 12.5% 35.7% 100.0% 
Female 
Count 15 35 12 33 95 
% 15.8% 36.8% 12.6% 34.7% 100.0% 
 Total 
Count 40 97 33 93 263 
% 15.2% 36.9% 12.5% 35.4% 100.0% 
 
P=0.997 
 
 It has been inferred from the table that grade IV tumours (the most 
malignant form of glioma) was common among male as compared to other 
grades of tumour. In WHO grade I and II tumours, there is an increase in 
incidence in females. This shows concurrence with the popular hypothesis that 
benign and low grade tumours are common in women while the more 
malignant forms are common in men. 
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CHART NO. 11 : CORRELATION OF SEX WITH   
WHO GRADE OF GLIOMA 
 
 
 
TABLE NO 12  DISTRIBUTION OF NUCLEAR 
PLEOMORPHISM IN  GLIOMAS 
Nuclear pleomorphism No of cases Percentage 
1+ 147 55.9% 
2+ 116 44.1% 
total 263 1005 
 
P-1+ -mild nuclear pleomorphism 
PP-2+ marked nuclear pleomorphism 
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CHART NO 12 : DISTRIBUTION OF NUCLEAR 
PLEOMORPHISM IN GLIOMAS 
 
 
TABLE  NO 13 A DISTRIDUTION OF MITOSES IN GLIOMAS 
 
MITOSES NO OF CASES PERCENTAGE 
ABSENT 29 11 
PRESENT 234 89 
TOTAL 263 100 
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TABLE NO 13-B    DISTRIBUTION OF VASCULAR  
PROLIFERATION IN GLIOMAS 
VASCULAR 
PROLIFERATION NO OF CASES PERCENTAGE 
ABSENT 99 37.6% 
PRESENT 164 62.3% 
Total 263 100% 
 
TABLE NO 13C-DISTRIBUTION OF NECROSES IN GLIOMAS 
NECROSES NO OF CASES PERCENTAGE 
Absent 169 64.3% 
Present 94 25.7% 
Total 263 1005 
 
Chart no 13 (A,B,C) DISTRIBUTION OF MITOSES,VASCULAR 
PROLIFERATION,AND NECROSES 
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TABLE 13 D : DISTRIBUTION OF CELLULARITY IN GLIOMAS 
CELLULARITY NO OF CASES PERCENTAGE 
Low 3 6%% 
Moderate 24 48% 
High 23 46% 
 
IMMUNOHISTOCHEMICAL  EXAMINATION OF   GLIOMAS – A 
CORRELATION WITH CD117 EXPRESSION 
 The expression of CD117 was studied in different grades of glioma. A 
subset of 50 cases constituting 9 cases of  WHO grade I tumours, 14 cases of 
WHO grade II tumours, 8 cases of WHO grade III tumours, and 19 cases of 
WHO grade IV tumours  were  selected as representative  of  the whole sample 
of 263 cases. The formalin fixed paraffin embedded sections of the selected 
cases was subjected to immunohistochemical analysis with CD117. The list of 
cases described below. 
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TABLE 14 LIST OF CASES STUDIED FOR CD117 EXPRESSION 
 
DIAGNOSES GRADE NO OF CASES 
PILOCYTIC ASTROCYTOMA I 9 
DIFFUSE  FIBRILLARY 
ASTROCYTOMA 
II 4 
OLIGO ASTROCYTOMA II 2 
PLEOMORPHIC 
XANTHOASTROCYTOMA 
II 1 
OLIGODENDROGLIOMA II 4 
EPENDYMOMA II 3 
ANAPLASTIC 
ASTROCYTOMA 
III 8 
GBM IV 19 
8 TYPES FOUR GRADES 50 
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TABLE NO 15   DISTRIBUTION OF CD117 EXPRESSION IN 
GLIOMAS 
PARAMETER POSITIVE NEGATIVE 
CD117 EXPRESSION 27(54%) 23(46%) 
 
CD117 was positive in 54% (27) of total cases. 
 
 
CHART NO 15 : CD 117 EXPRESSION 
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TABLE NO 16 CORRELATION OF CD117 EXPRESSION IN 
INDIVIDUAL GRADES 
 
 CD117_of_stained_cells Total 
NEG POS 
GRADE 
I Count 4 5 9 % 44.4% 55.6% 100.0% 
II Count 10 4 14 % 71.4% 28.6% 100.0% 
III Count 2 6 8 % 25.0% 75.0% 100.0% 
IV Count 7 12 19 % 36.8% 63.2% 100.0% 
Total Count 23 27 50 % 46.0% 54.0% 100.0% 
 
P=0.126 
CHART 16 Correlation of CD117 exp in individual grades 
 
 CDII7 expression was 56% positivity in WHO grade I gliomas. In case 
of grade II, grade III, and grade IV gliomas the percentage of positivity was 
29%, 75%, and 63% respectively. The maximum positivity was seen in grade 
III & IV gliomas.   
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TABLE 17.CORRELATION OF CD117 EXPRESSION WITH LOW  
GRADE (I&II) AND HIGH GRADES(III&IV)  GLIOMA 
 
 
 
CHART NO17: CORRELATION OF CD117 EXPRESSION WITH LOW  
GRADE (I&II) AND HIGH GRADES (III&IV)  GLIOMA 
 
 
 CD117  was positive in 39.13% of low grade tumours and 66.87% 0f 
high grade tumours inferring that maximum positivity was seen in high grade 
tumours .This correlation was found to be statistically significant.P <0.05 
CD117 EXPRESSION  WITH* GRADE Comparision P value 
  GRADE Total  
Low high  
CD117 
NEG 
Count 14 9 23  
% 60.87% 33.33% 46.00%  
CD117 
POS 
Count 9 18 27  
% 39.13% 66.67% 54.00%  
Total 
Count 23 27 50  
100.00% 100.00% 100.00% P< 0.05* 
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TABLE 18 : CORRELATION OF CD117  SCORE ( % OF STAINED 
CELLS) WITH GRADE 
 
SCORE 
Total 
0+ 1+ 2+ 3+ 4+ 
GRADE 
I 
Count 4 0 2 1 2 9 
% within 
GRADE 
44.4% 0.0% 22.2% 11.1% 22.2% 100.0% 
II 
Count 10 0 0 3 1 14 
% within 
GRADE 
71.4% 0.0% 0.0% 21.4% 7.1% 100.0% 
III 
Count 2 0 2 3 1 8 
% within 
GRADE 
25.0% 0.0% 25.0% 37.5% 12.5% 100.0% 
IV 
Count 7 4 8 0 0 19 
% within 
GRADE 
36.8% 21.1% 42.1% 0.0% 0.0% 100.0% 
Total 
Count 23 4 12 7 4 50 
% within 
GRADE 
46.0% 8.0% 24.0% 14.0% 8.0% 100.0% 
P=0.011* 
0=negative,  1+=0-10% stained cells ,2+ 11-50% stained cells,3+=51-
75% stained cells 4+=>75% stained cells. 
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 In WHO grade I gliomas 44.4 % were 0+ and  2+,3+,4+ positivity was 
found with percent of 22.2%, 11.1%, 22.2% respectively. 
 In WHO grade II gliomas  71.4% were 0+ and 3+ positivity (21.4% ) 
and 4+ positivity ( 7.1%)  
 In WHO grade III gliomas 25% are 0+ ,and 2+ positivity ,3+ positivity  
( 37.5%), 4+ positivity  in (12.5%) . 
 In WHO grade IV gliomas, 36.8 % were 0+, 21.1% were 1+ and 42.1% 
were 2+,  Highest scores of 3+ and  4+ was seen in WHO grade  III Tumours. 
So inferring that there is statistical correlation between CD117 score and grade 
of the tumour. ( P=0.011*) 
 
CHART NO 18: CORRELATION OF CD117  SCORE  
(% OF STAINED CELLS) WITH GRADE 
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TABLE 19 : CORRELATION OF GRADE WITH  CD117_stainigIntensity_ 
 
CD117_stainigIntensity_ 
Total 
NEG WEAK MOD STRONG 
GRADE 
I 
Count 4 1 2 2 9 
% 44.4% 11.1% 22.2% 22.2% 100.0% 
II 
Count 10 1 2 1 14 
% 71.4% 7.1% 14.3% 7.1% 100.0% 
III 
Count 2 3 1 2 8 
% 25.0% 37.5% 12.5% 25.0% 100.0% 
IV 
Count 7 6 4 2 19 
% 36.8% 31.6% 21.1% 10.5% 100.0% 
Total 
Count 23 11 9 7 50 
% 46.0% 22.0% 18.0% 14.0% 100.0% 
 
 WHO Grade I tumours show both moderate and strong staining intensity 
in equal percentage (22.2%) WHO.grade II tumours show more moderate 
staining intensity (14.3%). WHO Grade III tumours (37.5%)  and WHO grade  
IV tumours (22%) show more  weak  staining  .This study shows no statistical 
correlation between staining intensity and grade of the tumour  and thus not 
statistically significant.  
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CHART NO 19 CORRELATION OF GRADE WITH  
CD117_STAINIGINTENSITY 
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TABLE  20 
CORRELATION OF    AGE  VS  CD117_of_stained_cells 
 
CD117_of_stained_cells Total NEG POS 
 
UPTO 20 
YRS 
Count 6 5 11 
% 54.5% 45.5% 100.0% 
21-40 YRS Count 9 10 19 % 47.4% 52.6% 100.0% 
41-60 YRS Count 8 10 18 % 44.4% 55.6% 100.0% 
61-80 YRS Count 0 2 2 % 0.0% 100.0% 100.0% 
Total Count 23 27 50 % 46.0% 54.0% 100.0% 
P=0.560 
 In the above table, highest CD117 positivity was seen  in  age group of 
61-80 years. Second  highest  positivity was  seen in age group 41-60 years. 
 
CHART 20: CORRELATION OF AGE  VS  CD117 
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TABLE 21 
CORRELATION of CDII 7 EXPRESSION WITH SEX 
 
CD117_of_stained_cells Total NEG POS 
SEX 
F Count 7 9 16 % 43.8% 56.2% 100.0% 
M Count 16 18 34 % 47.1% 52.9% 100.0% 
Total Count 23 27 50 % 46.0% 54.0% 100.0% 
 
P=0.827 
 The above table shows that females have high (56.2 %) CD117 
positivity when compared to males (52.9%). 
 
CHART NO 21 CORRELATION OF CDII 7  EXPRESSION  WITH SEX 
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35%
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50%
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TABLE NO 22 
CORRELATION OF SIDE WITH CDII7 EXPRESSION 
 
 
CD117_of_stained_cells Total NEG POS 
SIDE 
L Count 6 11 17 % within SIDE 35.3% 64.7% 100.0% 
M Count 5 4 9 % within SIDE 55.6% 44.4% 100.0% 
R Count 12 12 24 % within SIDE 50.0% 50.0% 100.0% 
Total Count 23 27 50 % within SIDE 46.0% 54.0% 100.0% 
 
 In the above table highest percentage of CD117  positivity was seen in  
left  hemisphere (64.7%) 
 Right  hemisphere show 50% positivity, deep seated midline structures 
show 44.4%positivity. This study was not statistically significant .P=0.53 
 
CHART NO 22 CORRELATION OF SIDE WITH CDII7 EXPRESSION 
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TABLE NO 23 CORRELATION OF CD117 WITH OTHER 
HISTOLOGICAL PARAMETERS 
Tumour characteristics CD117 EXPRESSION CHI –
SQUARE 
TEST Description Negative Positive 
cellularity 
1Low 3 0 
P=0.041* 2moderate 13 11 
3high 7 16 
Nuclear 
pleomorphism 
1+ 16 11 
P=0.042* 
2+ 7 16 
Mitoses 
Absent 3 2 
P=0.508 
Present 20 25 
Vascular 
proliferation 
Absent 9 7 P=0.318 
Present 14 20 
 
Necroses 
Absent 15 16 
P=0.665 
Present 8 11 
 
         Correlation of  CD117 expression with cellularity shows that  those cases  
with  high cellularity had  highest percentage positivity (69.6%).The cases with 
low cellularity showed  nil  positivity. This study was statistically significant.P 
< 0.041 
            Correlation between nuclear pleomorphism and  CD117 expression 
showed  cells with  marked nuclear pleomorphism  had   increased CD117 
expression.The study was statistical significant.(P< 0.042.) 
           Correlation  of CD117 with mitoses ,vascular proliferation and necroses  
showed  no statsitical significance. There are no studies in literature to support 
it. 
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TABLE 24 : DISTRIBUTION OF CD117 EXPRESSION IN VARIOUS 
SUBTYPES OF GLIOMAS 
 
CD117_of_stained_cells 
Total 
NEG POS 
PA 
Count 4 5 9 
% 44.4% 55.6% 100.0% 
DFA 
Count 4 0 4 
% 100.0% 0.0% 100.0% 
PXA 
Count 1 0 1 
% 100.0% 0.0% 100.0% 
OA 
Count 1 1 2 
% 50.0% 50.0% 100.0% 
ODG 
Count 2 2 4 
% 50.0% 50.0% 100.0% 
AA 
Count 2 6 8 
% 25.0% 75.0% 100.0% 
% within DIAGNOSIS 100.0% 0.0% 100.0% 
EP 
Count 2 1 1 
% within DIAGNOSIS 66.66% 33.33% 100.0% 
GBM 
Count 7 12 19 
% within DIAGNOSIS 36.8% 63.2% 100.0% 
Total 
Count 23 27 50 
% within DIAGNOSIS 46.0% 54.0% 100.0% 
 
75 
 
 
CHART NO 24 : DISTRIBUTION OF CD117 EXPRESSION IN 
VARIOUS SUBTYPES OF GLIOMAS 
 
 
 
 Anaplastic astrocytoma showed highest expression percentage (75%), 
second highest expression was seen in glioblastoma multiforme (63.2)% 
pilocytic astrocytoma showed 55%, oligodendroglioma showed 50% positivity. 
Diffuse fibrillary astrocytoma was 100% negative. 
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TABLE NO 25  : CORRELATION OF CD117 STAINING INTENSITY 
IN GLIOMA HISTOLOGICAL SUBTYPES 
 
NEG WEAK MOD STRONG 
 
PA Count 4 1 2 2 9 % 44.44% 11.11% 22.22% 22.22% 18.00% 
DFA Count 4 0 0 0 4 % 100.00% 0.00% 0.00% 0.00% 100.00% 
PXA Count 1 0 0 0 1 % 100.00% 0.00% 0.00% 0.00% 100.00% 
ODG Count 2 1 0 1 4 % 50.00% 25.00% 0.00% 25.00% 100.00% 
OA Count 1 0 1 0 2 % 50.00% 0.00% 50.00% 0.00% 100.00% 
EPENDYMOMA Count 2 0 1 0 3 % 66.67% 0.00% 33.33% 0.00% 100.00% 
AA Count 2 3 1 2 8 % 25.00% 37.50% 12.50% 25.00% 100.00% 
GBM Count 7 6 4 2 19 % 36.84% 31.58% 21.05% 10.53% 100.00% 
TOTAL Count 23 11 9 7 50 % 46% 22% 18% 14% 100% 
 
CHART NO 25 : CORRELATION OF CD117 STAINING INTENSITY 
IN GLIOMA HISTOLOGICAL SUBTYPES 
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TABLE  NO 26 CORRELATION OF  CD117  SCORE  WITH GLIOMA 
HISTOLOGICAL TYPES 
 
SCORE Total 0+ 1+ 2+ 3+ 4+ 
PA Count 4 0 2 1 2 9 % 44.40% 0.00% 22.20% 11.10% 22.20% 100.00% 
DFA Count 4 0 0 0 0 4 % 100.00% 0.00% 0.00% 0.00% 0.00% 100.00% 
PXA Count 1 0 0 0 0 1 % 100.00% 0.00% 0.00% 0.00% 0.00% 100.00% 
OA Count 1 0 0 1 0 2 % 50.00% 0.00% 0.00% 50.00% 0.00% 100.00% 
AA Count 2 0 2 3 1 8 % 25.00% 0.00% 25.00% 37.50% 12.50% 100.00% 
ODG Count 2 0 0 1 1 4 % 50.00% 0.00% 0.00% 25.00% 25.00% 100.00% 
Ependymoma 
Count 2 0 0 1 0 3 
% 100.00% 0.00% 0.00% 100.00% 0.00% 100.00% 
GBM Count 7 4 8 0 0 19 % 36.80% 21.10% 42.10% 0.00% 0.00% 100.00% 
Total Count 23 4 12 7 4 50 % 46.00% 8.00% 24.00% 14.00% 8.00% 100.00% 
P=0.332  0=negative,  1+=0-10% stained cells ,2+ 11-50% stained cells,3+=51-75%, 
4+=>75% . 
 
CHART NO 26 : CORRELATION OF  CD117  SCORE  WITH GLIOMA 
HISTOLOGICAL TYPES 
CEEP, EP, EPEN – Ependymoma. 
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Correlation of individual  hpe  diagnoses with pattern of CD117 expression 
including,score and intensity of staining . 
 In pilocytic astrocytoma, out of the 9 cases  ,2 cases were strong 
positive,2 moderate,1 weak. positive. they had strong and weak positive of 
equal incidence,and more than 25% cells were stained in all cases. 
 Diffuse fibrillary astrocytoma - all the four cases  were negative. 
Oligodendroglioma - out of 4 cases, two showed positivity one was weak and 
one strong positive  in   > 50% of cells. Ependymoma - out of the three, one 
case was positive  which showed  moderate staining intensity  in > 50% cells. 
Oligoastrocytoma - out of the two cases one case was positive showing 
moderate staining intensity  in >  50% of cells. Pleomorphic xanthoastrocytoma  
was negative . 
 Anaplastic astrocytoma - out of the eight cases , 6 cases were positive ,2 
cases showed strong positivity,one moderate and 3 weak positivity.more than 
25% cells were stained in all cases ,one case showed more than 75% cells with 
strong positivity. Glioblastoma multiforme -12 cases showed positivity out of 
19 cases.6 cases weak positive ,four moderate ,and two strong positive.only 
less than 50% cells were stained in all cases.. 
 FIG 1: H & E 100 X PILOCYTIC ASTROCYTOMA 
 
 FIG NO 2: H & E 100X DIFFUSE FIBRILLARY ASTROCYTOMA 
 FIG 3: H & E 100X OLIGODENDROGLIOMA 
 
 
 
FIG NO 4: H & E 100X EPENDYMOMA 
True rosettes and pseudo rosettes 
 Fig NO 5: H & E 400 X ANAPLASTIC ASTROCYTOMA 
 
 
FIG NO 6: H & E 100 X GLIOBLASTOMA MULTIFORME 
Endothelial proliferation and pseudopalisading necroses 
 FIG 7: IHC CDII7 STRONG POSITIVE IN PILOCYTIC ASTROCYTOMA 
 
 
 
 
 
FIG NO 8: CD117 SHOWING MODERATE POSITIVITY IN 
OLIGODENDROGLIOMA 
 FIG NO 9: CD117   POSITIVE IN EPENDYMOMA 
 
 
 
FIG NO 10: CD117 POSITIVE IN ANAPLASTIC ASTROCYTOMA 
  
 
 
 
 
FIG NO 11: CD117 POSITIVE IN GLIOBLASTOMA MULTIFORME 
 
 
 
 
 
 
 
 
 
 FIG 12: MRI PICTURE - PILOCYTIC ASTROCYTOMA  
 
 
 
FIG 13: MRI PICTURE - EPENDYMOMA CONTRAST ENHANCING 
LESION IN FLOOR OF FOURTH VENTRICLE 
 FIG NO 14: MRI PICTURE - OLIGODENDROGLIOMA 
 
 
FIG  NO 15: MRI PICTURE - GLIOBLASTOMA MULTIFORME  
 
  
 
DISCUSSION 
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DISCUSSION 
 The incidence of nervous system tumours is increasing in both 
developed and developing countries in the present era involving adults. 
Paediatric  population  also show increasing occurrence of nervous system 
tumours. CNS  tumours  are rare neoplasms with 1-3% incidence129  .Gliomas 
are most common malignancies in CNS tumours and they account for  40% of 
all primary brain neoplasms130. 
 
 In the present study, histomorphological  analysis  was done for 263 
cases of   glioma while immunohistochemical evaluation was done for a subset 
of 50 cases . An evaluation of  CD117  expression in cases of  gliomas were 
done. 
 Madras Medical College being a tertiary referral centre, the relative 
frequency of  gliomas  among the   neurosurgical cases  was 31.4%   among  
the  entire  neurospecimens.  
 
 In our   study the peak incidence of gliomas was 41 -60 years. The 
maximum age observed was 85 years. It showed a  mean age  of  38 years with 
a standard deviation of 19.6. This is similar to study of Gurney et al(131), . and 
Vovoras et al132   
 
 WHO grade 1 tumour was  most  common in age group of less than 20 
years (53.3%. ).WHO grade II  was  most commonly seen in age group of 21-
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40 years( 50.6 %.). WHO grade III and IV tumours are commonly seen  in  the 
age group above 80 years (75%). There are no studies to correlate the age and 
grade of the tumours. 
 
Comparision of sex incidence of gliomas. 
 In our study  gliomas have  a male preponderance , that is out of the 263 
cases studied  63.9 % (168)  of cases have occurred in males and 36.1 % (95 
cases) of cases have occurred in females. This correlates with study of 
vovorosa et al (132)lbut does not correlate with ICMR studies.133. 
 
TABLE NO 27 : COMPARISION OF SEX INCIDENCE OF GLIOMAS 
 Current  study Vovorosa et al 
MALE 63.9% 55.6% 
FEMALE 36.1% 44.45% 
 
 The median age at diagnoses is higher in males than females. It 
correlates with observation of denis strongman et al from australia.(130)  
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TABLE NO 28 COMPARISION OF MEDIAN AGE AT DIAGNOSIS 
 
 
DENIS STRANGMAN 
ET AL 
CURRENT STUDY 
MALE 60-64 40 
FEMALE 55-59 37 
 
Comparision of distribution of histopathological subtypes of    gliomas  
 From the  data in our institute   it is clear that  out of the 263 gliomas 
studied in a two year period  Glioblastoma multiforme was the most common 
one accounting for 94 cases (35.7%). Pilocytic astrocytoma was the second 
most common  glioma accounting for  38 cases (14.4%). Least common were 
pleomorphic xanthoastrocytoma (1.1%), oliogoastrocytoma(1.9%), 
anaplasticoliogoastrocytoma,(0.8%), Anaplastic oligodendroglioma(0.8)%. 
These findings are in correlation with study of Larjavaara etal (134) 
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TABLE NO 29 COMPARISION OF DISTRIBUTION OF  
HISTOPATHOLOGICAL SUBTYPES OF    GLIOMAS 
 
Comparision of side of brain involved in glioma 
 In our study, Right hemisphere of brain was most commonly involved 
44.8% than the left 33.07%, and other midline deep structures 22.05% .This 
correlates with study of larjavara et al134 
 
TABLE NO 30 COMPARISION OF SIDE OF BRAIN  
INVOLVED IN GLIOMA 
SIDE Current study Larjavara et al 
Right 44.8% 50 
Left 33.07% 41 
Midline 22.05 9 
 
  Our study Larjavaara et al.: 
1.  Pilocytic Astrocytoma 14.4 5 
2.  Diffuse  astrocytoma 7.6 14 
3.  Oligo astrocytoma 1.9 10% 
4.  Oligodendroglioma 7.6 11%         
5.  Ependymoma 9.1 3% 
6.  Anaplastic Astrocytoma 8.0 9% 
7.  Glioblastoma Multiforme 35.7 47% 
8.  Other Gliomas 7% <1% 
9.  Other Astrocytoma 2.7% <1% 
 Total 100.0  
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Comparision of   site incidence of gliomas  
 In our study The cerebral lobes  is   most commonly involved by the 
glioma that is 79% of which frontal lobe has the highest incidence of cases 
accounting to 19.8 %( 52 cases). The second most common is the 
temporoparietal   region  accounting to 12.9 %( 34 cases).The occipital lobe 
showed the least common involvement accounting to(4.6%)12 cases.  
 The  findings  in  our  study  is  more  or  less  similar to the study of 
Larjavaara et al,  except  for parietal lobe involvement which  is only 6.5% in 
our study when compared to Larjavaara et al134in which  the  parietal lobe 
involvement  was 14%. 
TABLE  NO 31 ;SITE INCIDENCE OF GLIOMAS COMPARATIVE 
STUDY 
 Larjavaara et al Our study 
Frontal 40% 44.2% 
Temporal 29% 24.3% 
Parietal 14% 6.5% 
Occipital 3% 4.6% 
Cerebellum 1.5% 2.7% 
Ventricles 2.2% 5.3% 
Brain stem 4.1% 10.9% 
Deep structures areas 14% 10.5% 
 
 In our study ,in the spinal cord out of the 14 cases, intradural 
intramedullary  lesions were most common accounting to 10 cases(3.8% ) 
,intradural extra medullary  lesions was second most common accounting to     
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3 cases (1.1% ) and   one case was  extradural lesion accounting to 0.4% of 
total cases. There are no studies in literature to correlate these lesions. 
 
Comparision of WHO grade of tumours 
 In our study, it  was  found  that  the  WHO  grade  II   tumours   were  
of  maximum  incidence ( 36.9 %),the second most common was WHO grade 
IV tumours(35.4%) ,the third common was WHO grade I tumours( 15.2%),and  
fourth place was taken  by WHO grade  III tumours( 12.5 %.) These 
observations  correlated with studies of  Larjavara et al.134 
 
TABLE NO 32 
WHO GRADE LARJAAVARA ET AL CURRENT STUDY 
I 5.13% 15.2% 
II 38.9% 36.9% 
III 9.36% 12.5% 
IV 46.5% 35.4% 
 
 
Comparision of  grade   with sex  
 It has been inferred from the table that WHO  grade IV tumours  ( the 
most malignant form of glioma) was common among male as compared to 
other grades of tumour. WHO grade I and II tumours - slight increase in 
incidence in females. This shows concurrence with the popular hypothesis that 
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benign and low grade tumours are common in women while the more 
malignant forms are common in men. There are no studies found in literature. 
The sex distribution of gliomas   in our study did not correlate with study of 
vovorosa et al. 
Comparision of  diagnosis   with sex (Table – 34) 
              In  our study  most of the tumours  have male predilection except 
oligoastrocytoma and ependymoma which show female predominance.These 
findings did not correlate with the study of  vovorosa et al.132 
 
TABLE NO 34 
Tumour types 
D. Vovoras et al 
Our study 
Sex 
Males Males 
Specified low grade astrocytic 
tumor 56.31 14.88% 
Glioblastoma and anaplastic 
astrocytoma 57.11 44.64% 
Astrocytoma NOS 55.13 28% 
Other Glioma 54.68 6.54% 
Ependynoma 55.06 8.333 
 
 
Comparision of tumour  types with age groups (Table – 35) 
 Pilocytic astrocytoma was found  to  most  commonly affect the age  
group of  0 to 20 years. Myxopapillary ependymoma was found commonly to 
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affect the age group of 20- 40 years. Diffuse fibrillary astrocytoma was most  
commonly affect the age group of 21-40 years.Diffuse astrocytoma showed 
maximum incidence in  20-60 years.Pleomorphic xanthoastrocytoma- three 
cases were studied, two cases occurred in 41-60 years. ( 66.7 %). Anaplastic 
astrocytoma , occurred in 21-40 years age group following a relative percent of 
57.1% . Glioblastoma multiforme  maximum  cases  occurred  in  an  age group 
of 41-60 years with 60.6%. Above study correlates with the study of  
Dr.D.vovorasa et al132 
TABLE NO 35 
Types 
D. Vovoras et al OUR STUDY 
AGE age   
0-19 20-64 >65 0-19 20-64 >65 
Specified low 
grade astrocytic 
tumor 
1820 
(32%) 
1743 
(6%) 
347 
(2%) 
33 
(55%) 
8 
(5%) 
0 
(0%) 
Glioblastoma and 
anaplastic 
astrocytoma 
605 
(11%) 
14858 
(52%) 
12496 
(72%) 
2 
(3%) 
93 
(53%) 
20 
(77%) 
Astrocytoma 
NOS 
1315 
(23%) 
5165 
(18%) 
2385 
(14%) 
4 
(7%) 
41 
(23%) 
4 
(15%) 
Other Glioma 1399 (24%) 
5544 
(19%) 
1971 
(11%) 
3 
(5%) 
23 
(13%) 
2 
(8%) 
Ependynoma 588 (10%) 
1204 
(4%) 
184 
(1%) 
18 
(30%) 
12 
(7%) 
0 
(0%) 
 5727 28514 17383 60 177 26 
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IMMUNOHISTOCHEMISTRY IN NERVOUS SYSTEM TUMOURS: 
 The expression of CD117 was studied in different grades of glioma. A 
subset of 50 cases constituting  of all four   grades of glioma as representative 
of  sample of 263 cases was analysed immunehistochemically. The formalin 
fixed paraffin embedded section was subjected to immunohistochemical 
analysis with  CD117. 
 Among the 50 CASES CD117 expression  was seen  in 54% of tumours.  
 
TABLE NO 36 COMPARISION  OF  CD117  POSITIVITY WITH  
WORLD STATISTICS 
Cetin et al 75% 
Parvin et al 76% 
arash degan et al. 42% 
Current  study 54% 
 
 CD117 expression  was lower than the studies of  parvin et al127,and 
cetin et al, higher than studies of  arash degan et al128. 
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 COMPARATIVE  STUDY   OF   CD117   POSITIVITY WITH GRADE  
TABLE NO 37 COMPARISON OF  CD117 POSITIVITY WITH GRADE 
AS LOW AND HIGH GRADE 
 
CURRENT 
STUDY Parvin et al 
Arash deghan et 
al 
Low 39.13 68% 21.2% 
High 66.67 84% 61.1% 
 
 CD117  was positive in  39.13 % of low grade tumours and 67% of high 
grade tumours  inferring that  maximum positivity was seen in high grade 
tumours .This correlation was found to be statistically significant with P value 
of0.05*.The study correlated with study of parvin et al127,arash devgan et al 128. 
COMPARATIVE STUDY OF % EXPRESSION OF CELLS WITH  
GRADE OF THE TUMOUR 
TABLE NO 38 COMPARATIVE STUDY OF % EXPRESSION OF 
CELLS WITH  GRADE OF THE TUMOUR 
SCORE CURRENT STUDY PARVIN ET AL 
 Low High Low High 
0+ 60.86% 33.33% 32 16 
1+ 0 14.81% 12 8 
2+ 8.69% 37.03% 28 32 
3+ 17.39% 11.11% 28 16 
4+ 13.04% 3.7% 0 28 
0=negative, 1+=0-10% stained cells ,2+ 11-50% stained cells,3+=51-75%  
4+=>75% .128 
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  Low grade gliomas had maximum % of 3+ and high grade gliomas had 
maximum % of 2+.This observation  did not correlate with the studies of 
parvin et al.127 
 
Comparision  of  the intensity of stained  cells with grade of the tumour-
(TABLE NO 39) 
 WHO Grade I tumours show both moderate and strong staining intensity 
in equal percent (22.2)%.WHO GRADE II tumours show   more  of moderate 
staining intensity.(14.3%) WHO Grade III tumours (37.5%)  and IV tumours 
(22%) show more  of weak  staining. This study shows no statistical correlation 
between staining intensity and grade of the tumour  These observations did not 
correlate with study of parvin et al.127 
TABLE NO 39 
 Parvin et al Current study 
 LOW-25 HIGH-25 LOW-23 HIGH-27 
NO 32% 16% 60.8% 33.33% 
Weak 36% 32% 17.39% 33.33% 
Moderate 24% 32% 8.69% 18.51%% 
STRONG 8% 20% 13.04% 14.8% 
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Comparision of individual  HPE  diagnoses with pattern of CD117 
expression including score and intensity of staining .(Table -40) 
 In pilocytic astrocytoma, out 9 cases, 2cases strong positive,2 
moderate,1 weak positive and  more than 25% cells were stained in all cases. 
          Diffuse fibrillary astrocytoma and Pleomorphic xanthoastrocytoma    
were negative. 
          Oligodendroglioma - out of 4 cases two showed positivity one was weak 
and one strong positive , in  > 50% of cells  in both cases. 
           Ependymoma- out of the three cases  one case was positive showing  
moderate staining intensity in >  50% cells. 
 Oligoastrocytoma- out of the two cases one was positive showing 
moderate staining intensity  in > 50% of cells.. 
 Anaplastic astrocytoma - out of the eight cases studied  6 cases were 
positive ,2 cases showed strong positivity,one moderate positive and  3 were 
weak positive and more than 25% cells were stained in all cases ,one case 
showed 4+ with  strong staining  intensity. 
Glioblastoma multiforme -12 cases showed positivity out of 19 cases.6 cases 
were  weakly stained ,four moderately stained ,and two strong  positive. Only 
less than 50% cells were stained in all cases. 
 Our study did not correlate with study of arash devgan et al 128in cases 
of pilocytic astrocytoma ,diffuse astrocytoma and oligodendroglioma. It 
coincided in cases of ependymoma ,anaplastic astrocytoma,and glioblastoma 
multiforme. 
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TABLE NO 40 COMPARISION OF CD117 EXPRESSION SCORE  IN 
GLIOMA SUBTYPES WITH OTHER STUDIES. 
DIAGNOSIS 0+ 1+ 2+ 3+ 4+ 
Pilocytic 
astrocytom
a 
Arash devgan 
et al 
4 0 0 o O 
100%     
Current  
STUDY 
4 0 2 1 2 
44.4% 0.0% 22.2% 11.1% 22.2% 
Diffuse 
astrocytom
a 
Arash devgan 
et al 
17 1 3   
81% 5% 14%   
Current study 
4 0 0   
100% 0 0   
Oligodendr Arash devgan 
et al 
4 1 0   
80% 20% 0   
Oglioma 
 
Current study 
% 
2 0 0 1 1 
50 % 0.0% 0.0% 25.0% 25.0% 
ependymo
ma 
Arash devgan 
et al % 
1 2    
33.3% 66.6%    
 
Current study 
% 
2 0 0 1  
66.66
% 0 0 
33.33
%  
Anaplastic 
astrocytom 
Arash devgan 
et al % 
3 3 1   
43% 43% 14%   
Current study 
% 
2 0 2 3 1 
25.0
% 0.0% 
25.0
% 
37.5
% 12.5% 
GBM 
Arash devgan 
et al % 
 
8 7 1 1 0 
47% 41% .05% .05% 0 
Current study 
% 
7 4 8 0 0 
36.8
% 
21.1
% 
42.1
% 0.0% 0.0% 
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Comparision of histopathological parameters (Cellularity, Nuclear 
pleomorphism, Mitosis, Vascular proliferation and necrosis) with CD117 
expression.    
 In our study  those cases which  had high cellularity  had  highest 
percentage positivity(69.6%).The cases with low cellularity showed  nil  
positivity. This study is statistically significant.P < 0.041. 
 In our study there was significant correlation found between nuclear 
pleomorphism and  CD117 expression.The cells with  marked nuclear 
pleomorphism showed  increased CD117 expression P<0.042. 
 Correlation  of CD117 with mitoses ,vascular proliferation and necroses 
showed no statsitical significance. There are no studies in literature to support  
CD117 expression with histological parameters. 
 There are no studies to compare the Histological parameters with 
CD117 expression in literature. 
 
Comparison of CD117 with Age, Sex and Side 
 Comparison of CD117 with age  shows highest  CD117 positivity   in  
age group of 61-80 years  age.  
 On Comparing CD117 with sex, among the CD117 positive cases 
percentage positivity in females was high (56.2 %) when compared to males ( 
52.9%) . 
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 Comparision of CD117 with  side of gliomas shows   highest percentage 
of CD117  positivity  in  left  hemisphere (64.7%) Right  hemisphere show 
50% positivity. Deep seated midline structures show 44.4% positivity. There 
are no studies to correlate CD117 positivity with age, sex and side of the lesion. 
STRENGTH AND LIMITATIONS OF THIS STUDY: 
STRENGTH OF THIS STUDY: 
1. Study covers a period of 2 years done at a tertiary care hospital in south 
India. 
2. The clinicopathological aspects of glioma- their relative incidence, age 
distribution, sex predeliction, site involvement has been enumerated and will be 
of value in estimating the same for a ftrure population based study. 
3. the strong association of CD117  expression in various grades of glioma, 
with the maximum intensity seen in grade III glioma has been shown by our 
study. 
LIMITATIONS OF THIS STUDY: 
1. Study is hospital based, hence does not reflect the true incidence and 
prevalence in the community. 
2. Due to economic constraints, the entire cases could not be evaluated  with 
immunohistochemistry. 
3. Follow up was not available . 
  
 
SUMMARY 
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SUMMARY 
• In the present study, histomorphological  analysis was done for 263 
cases of   glioma while immunohistochemical evaluation was done for a 
subset of 50 cases .CD 117 expression was assessed in these cases. 
• The peak incidence of glioma was seen in 41-60 years , while least 
incidence of glioma was seen in age group more than 80   years. 
• 41-60 years is the most common age group affected  by glioma. 
• The median age at diagnosis  in males was 40 years,and 37 years in 
females 
• Gliomas show a male preponderance. Total number of  gliomas in males 
was 168cases( 63.9%) and in females was 95 cases(36.1%) 
•  Glioblastoma multiforme was the most common glioma in our institute 
and Pilocytic astrocytoma was the second most common  glioma . 
• Right hemisphere of brain was most commonly involved than left. 
• The cerebrum is most commonly involved by the glioma, of which  
frontal lobe is the most common site . 
•  Most of the Glioma are  WHO  grade  II   followed by WHO  grade IV 
tumours  
• WHO grade 1 tumour were more common in age group of less than 20 
years. WHO grade II  was  most common in age group of 21-40 years . 
WHO grade III and IV tumours were common in  the age group  above 
60 years   
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• CD117 was positive in 54% of total cases. 
• CD117 was positive in 39.13 % 0f low grade tumours and 66.8% 0f high 
grade tumours.(p value <0.05) 
• Highest CD117 score was seen in WHO grade III tumours with  P value 
of  0.011. 
• The cells with  marked nuclear pleomorphism showed  increased CD117 
expression which wass statisticaly significant.(P< 0.042) 
• On correlating CD117 expression with cellularity,  those cases which 
had high cellularity showed  highest percentage of  positivity which was 
statistically significant.P < 0.041 
• Highest CD117 positivity was seen in 61-80 years age group followed 
by 41-60 years. 
• Females show maximum CD117 positivity with 56.2% and males show 
52.9% positivity 
• Highest percentage of CD117 positivity is seen in Left hemisphere 
tumours(64.7%). Right hemisphere tumours show 50% positivity. 
Tumours in the deep seated midline structures show 44.4% positivity. 
                                                 
  
 
  
  
 
CONCLUSION 
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                                   CONCLUSION 
Incidence of gliomas are on the rise .Brain tumours are different from 
other tumours, as prognosis depends on the site of the tumour and most 
tumours are less amenable for surgery. In our study, CD117 is expressed 
remarkably in high grade tumours than in low grade tumours. Hence CD117 
can be used as a perfect tool to identify these tumours and thus make them 
amenable to chemo therapy with tyrosine kinase inhibitors like Imatinib, which 
is already proven and in vogue in gastrointestinal stromal tumour. 
This study opens the vision on targeted therapy in gliomas of high 
grade. 
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ANNEXURES 
  
ANNEXURE I 
 
 
  
   
ANNEXURE II 
PROFORMA 
Case no :       OP/IP NO : 
Name :      Biopsy No : 
Age : 
Sex : 
Clinical diagnosis : 
Symptoms : 
 
H/O Recurrence : 
Risk factors any : 
CT/MRI findings : 
Site :       Contrast enhancement : 
Side :        Ventricle obstruction : 
Solid :        Cystic with mural nodule : 
Cystic : 
Type of surgery : 
Gross : 
Size: 
Papillary excrescence: 
 Necrosis: 
Microscopy : 
Cellularity 1-low        2-moderate       3- high 
Nuclear pleomorphism  1+  mild           2+  marked 
Mitoses        A-absent                  P- present 
Vascular proliferation  absent/present 
Necroses absent/present 
 
Histological typing : 
 
WHO grading: 
Grade I   Grade III 
Grade II   Grade IV 
 
IHC RESULTS : CD117   1.Positivity & 
  2. Semi quantitative Score (1-4+) 
 3.Staining intensity     weak 
 Moderate  
 strong 
CD117 : 
 
 
 
 
 
 
 ANNEXURE II 
 
 
ANNEXURE IV 
WHO CLASSIFICATION OF CNS TUMOURS 
 
  
  
ANNEXURE V 
Immunohistochemistry procedure: 
Slide Preparation: 
1. Sections with a thickness of 4 µ were cut from formalin fixed 
paraffin embedded tissue samples and transferred to gelatin-
chrome alum coated slides. 
2. The slides were incubated for overnight at 58ºC. 
3. The sections were  deparaffinised in xylene for 15 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 5 minutes 
for 2 changes. 
5. Then the sections were  washed with  tap water for 10 minutes. 
6. The slides are  then immersed in distilled water  upto  5 minutes. 
 
Antigen Retrieval: 
1. Heat induced antigen retrieval was done with microwave oven in 
appropriate temperature with appropriate buffer for 20 minutes. 
This step unmasks the antigenic determinants of fixed tissue 
sections. 
2. The slides were then cooled to room temperature for 20 minutes 
and washed with tap water for 5 minutes. 
3. The slides were then rinsed with  distilled water for 5 minutes. 
4. then the slides were washed with appropriate wash buffer 
(phosphate buffer) for 5 minutes x 2 changes. 
5. Peroxidase block was then applied  for 10 minutes. 
6. The slides then were washed in phosphate buffer for 5 minutes x 2 
changes. 
7. Sections were covered with protein block for 5 minutes. 
  
Antibody application: 
1. The sections were drained (without washing) and appropriate 
primary antibody is  applied  and incubated for 30 minutes. 
2. The slides were washed in  the phosphate buffer for 5 minutes x 2 
changes. 
3. The slides were covered with Primary antibody amplifier for 10 
minutes. 
4. The slides were washed in the phosphate buffer for 5 minutes x 2 
changes. 
5. The slides were covered with HRP micropolymerQuanto for 10 
minutes. 
6. The slides were washed in  the phosphate buffer for 5 minutes x 2 
changes. 
 
Chromogen application: 
1. DAB substrate was prepared by diluting 1 drop of DAB 
Quantochromogen to 1 ml of DAB Quanto buffer. 
2. DAB substrate solution was applied on the sections for 5 minutes. 
3. wash the slides then in distilled water for 2 minutes. 
4. counterstain  the section with Hematoxylin  for 2 seconds. 
5. wash the slides in running tap water for 5 minutes. 
6. air dry the slides, cleared with xylene and mounted with DPX. 
 
Alternate methods of antigen retrieval 
• Pressure cooker antigen retrieval 
• Microwave and trypsin antigen retrieval 
  
MASTER CHART-statistics for two years fromjan 2013 to dec 2014 
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1 /1/13 45 M L FT GBM HGG 3 PP P 
 
P 
  
GBM 4 
   
2 3/13 46 M L FT GBM HGG 2 PP P P P 
  
GBM 4 
   
3 4/13 51 M L P BRAIN ABCESS HGG 2 PP P P P 
  
GBM 4 
   
4 5/13 51 M R F LGG HGG 1 P P A A 
  
DFA 2 
   
5 6/13 37 F L F HGG HGG 3 PP PP P A 
  
AA 3 
   
6 11/13 35 M L F CCG HGG 2 P P P P 
  
GBM 4 
   
7 12/13 60 M L P CYSTIC SOL HGG 2 PP P P P 
  
GBM 4 
   
8 14/13 63 M R TP HGG HGG 3 PP P P P 
 
GIANT 
CELL RICH 
GBM 4 
   
9 18/13 50 M R F LGG LGG 2 P A A A 
  
DA 2 
   
10 19/13 67 M L TP HGG HGG 2 PP P P P 
  
GBM 4 
   
11 21/13 83 M L TP HGG HGG 2 PP P P P 
  
GBM 4 
   
12 26/13 4 M M PO FO EP LGG 2 P P A A 
  
EP 2 
   
13 28/13 56 M R TP HGG HGG 2 P P A A 
  
GBM 4 
   
14 31/13 35 M M FP HGG HGG 2 P A A A P 
 
DFA 2 
   
15 33/13 14/M M SC IMSOL 
ASTROCYTOM
A 
LGG 2 P A A A 
  
PA 1 
   
16 34/13 18 M SC IMSOL LGG EP 2 P P A A 
  
DA 2 
   
17 36/13 22 M R FP LGG PA 2 P A A A 
  
PA 1 
   
18 37/13 60 F R TP HGG GBM 3 PP P P P 
  
GBM 4 
   
19 38/13 2 F M PF LGG EP 2 PP P A A 
 
CLEAR 
CELL 
EP 2 
   
20 43/13 22 M M 
CEREBEL
LUM 
REC ASTRO LGG 2 P A A A 
  
PA 1 
   
21 44/13 27 F M BG HGG HGG 2 P A A A 
  
GBM 4 
   
22 46/13 35 M R FT LGG LGG 1 P P A A 
  
DA 2 
   
23 56/13 35 m R TP HGG HGG 3 PP P P P 
 
ODG DIFF GBM 4 
   
24 63/13 1 MCH M PF MEDUL PA 2 P P A A 
  
EP 2 NEG 
 
0+ 
25 68/13 50 M L FTP HGG HGG 2 P A A A 
  
PA 1 
   
26 69/13 12 MCH R FTP PNET PA 2 P A A A 
  
PA 1 POS WEAK 2+ 
27 88/13 40 F R P ABCESS HGG 2 PP P P P 
  
GBM 4 NEG 
 
0+ 
28 94/13 37 M R F LGG HGG 3 PP P P A 
  
AA 3 
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29 96/13 60 F L P HGG HGG 3 PP P P P 
  
GBM 4 POS MOD 2+ 
30 104/13 10 F R T HGG C EP 3 PP P P P 
  
AEP 3 
   
31 105/13 65 M L F HGG DFA 3 PP P P A 
  
AOA 3 
   
32 124/13 34 M R FP LGG DFA 2 PP P A A 
  
DFA 2 
   
33 127/13 8 M R BG LGG LGG 1 P P A A 
  
PA 1 
   
34 130/13 64 F L P HGG HGG 3 PP P P P 
  
GBM 4 
   
35 134/13 67 F L PO HGG HGG 3 PP P P P 
  
GBM 4 
   
36 137/13 18 M R T LGG LGG 1 P P A A 
  
PA 1 NEG 
 
0+ 
37 140/13 37 M R BG LGG LGG 1 P A A A 
  
DA 2 
   
38 143/13 46 M R T HGG HGG 1 PP P P P 
  
GBM 4 
   
39 145/13 50 M L TP LGG LGG 1 PP P A A 
  
PA 1 
   
40 146/13 68 M L T HGG HGG 3 PP P A A 
  
GBM 4 
   
41 147/13 85 M L F HGG HGG 2 P P A P 
  
AA 3 NEG 
 
0+ 
42 152/13 30 M M BS LGG HGG 2 P P P A 
  
AA 3 POS MOD 3+ 
43 153/13 47 M L FP HGG HGG 3 P P P P 
  
GBM 4 
   
44 154/13 18 M M IMSOL MENINGIOMA EPEN 3 P P A A 
  
GG 2 
   
45 156/13 42 M M T GLIOMA LGG 1 P A A A 
  
DFA 2 NEG 
 
0+ 
46 159/13 7 M M BS LGG LGG 1 P A A A 
  
PA 1 
   
47 164/13 34 F M PO FO EPEN EPEN 3 P A A A 
  
EP 2 
   
48 167/13 11 F R T HGG HGG 3 P P P P 
 
ODG 
DIFFWITH
SMALL 
CELL 
GBM 4 
   
49 175/13 51 M R F ODG ODG 3 P P A A P 
 
ODG 2 
   
50 176/13 32 F L T DFA DA 3 P P A A 
 
GEMISTO
CYTES 
GA 3 
   
51 185/13 48 F L TP HGG HGG 3 PP 
    
ODG DIFF GBM- 4 POS WEAK 2+ 
52 189/13 43 M L FP MENINGIOMA HGG 3 PP P P P 
  
GBM 4 
   
53 191/13 5 M M BS TB LGG 2 P P A A 
  
PA 1 
   
54 192/13 42 M R TP HGG HGG 3 P P P P 
  
GBM 4 NEG 
 
0+ 
55 197/13 18 M M IMSOL LGG 
 
2 P P P A P 
 
GG 2 
   
56 202/13 30 M L TP HGG AA 2 P P P A P 
 
AEP 3 
   
57 203/13 12 M R FTP HGG HGG 3 P P A A 
  
PA 1 
   
58 206/13 45 F R FTP HGG HGG 3 P P P A 
  
GBM 4 
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59 210/13 53 F R P HGG HGG 2 P P A A 
  
AA 3 
   
60 219/13 28 M R P HGG AE 3 P P P A 
 
GC GBM 4 
   
61 226/13 14 M R TP LGG LGG 3 P P P P 
  
PA 1 
   
62 228/13 55 F R P HGG HGG 3 PP P P P 
  
GBM 4 
   
63 230/13 57 M R P HGG HGG 3 PP P P P 
  
GBM 4 
   
64 237/13 28 M R ID EM LGG 
 
2 P A A A 
  
MPEP 1 
   
65 238/13 52 M R FT HGG HGG 2 PP P P P 
  
GBM 4 
   
66 239/13 9 M M OC PIT ADENOMA LGG 2 P A A A 
  
PA 1 
   
67 245/13 52 M M CCSOL HGG HGG 3 PP P P P 
  
GBM 4 
   
68 247/13 12 F M PO FO 
MURALNODUL
E 
PA 2 P A A A 
  
PA 1 
   
69 249/13 13 M M PO FO 
MURALNODUL
E 
PA 2 P A A A 
  
PA 1 NEG 
 
0+ 
70 250/13 60 F R TP HGG HGG 3 PP P P P 
  
GBM 4 POS WEAK 1+ 
71 256/13 65 M R FP HGG HGG 3 PP P P P 
  
GBM 4 POS WEAK 2+ 
72 262/13 37 F R 4TH VEN LGG EP 3 PP A A A 
CELLUL
AR 
PSAMOM
A 
EP 2 NEG 
 
0+ 
73 275/13 48 M L T METS HGG 3 PP P PP P 
  
GBM 4 POS MOD 2+ 
74 279/13 33 M L F LGG LGG 2 P P A A 
  
DFA 2 NEG 
 
0+ 
75 281/13 6 M R FP HGG 
INADEQ
UATE 
2 PP P P P 
  
GBM 4 NEG 
 
0+ 
76 283/13 60 F R FP HGG HGG 3 PP P P P 
  
GBM 4 
   
77 288/13 38 M R T GLIOMA AA 3 PP P A A 
  
AA 3 
   
78 298/13 21 F L T GLIOMA 
 
2 P A A A 
  
GG 2 
   
79 310/13 31 M R TP GLIOMA 
 
2 P A A A 
  
GG 2 
   
80 314/13 7 M M SS CP CP 2 P A A A P 
 
PA 1 
   
81 316/13 32 M L FTP HGG HGG 3 P P P A 
  
AA 3 POS 
STRO
NG 
3+ 
82 321/13 35 M L TP HGG HGG 2 P P P A 
  
AA 3 
   
83 322/13 42 M M CC SOL GLIOMA LGG 2 P P A A 
  
DA 2 
   
84 324/13 65 F R 
CEREBEL
LUM 
LGG LGG 3 P P A A 
  
DA 2 
   
85 334/13 53 F R T HGG HGG 3 PP P P P 
  
GBM 4 
   
86 337/13 34 M R F HGG HGG 3 PP p p A 
  
AA 3 
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87 342/13 46 M L F LGG LGG 2 P P A A 
  
DFA 2 
   
88 354/13 42 M R T HGG HGG 3 PP P P P 
  
GBM 4 
   
89 359/13 8 MCH M PO FO LGG LGG 2 P P P A 
  
PA 1 
   
90 370/13 9 M M PO FO LGG EP 3 PP P P A 
 
CELLULAR EP 2 
   
91 371/13 47 M L F AA HGG 3 PP P P A 
 
GEMISTO
CYTES 
AA 3 POS WEAK 3+ 
92 372/13 49 M L F GLIOMA DA 2 P P P P 
  
GBM 4 NEG 
 
0+ 
93 373/13 44 M R FTP GLIOMA PA 2 P P P A 
  
DFA 2 NEG 
 
0+ 
94 390/13 30 F R F LGG LGG 2 P P A A 
  
DFA 2 
   
95 393/13 32 F R T LGG LGG 2 P P A A 
  
DFA 2 
   
96 394/13 43 F L TP HGG HGG 3 P P P A 
  
AA 3 NEG 
 
0+ 
97 397/13 58 M R TP GLIOMA HGG 3 PP P P A 
  
AA 3 
   
98 398/13 32 F M BS EPEN EP 3 P P P A 
  
EP 2 
   
99 401/13 53 F R 
CEREBEL
LUM 
GLIOMA LGG 2 PP P P A 
  
EP 2 
   
100 403/13 34 M R TP GLIOMA LGG 2 P P P A 
  
DFA 2 
   
101 405/13 7 F L 
CP 
ANGLE 
GLIOMA PA 2 P P A A 
  
PA 1 
   
102 406/13 65 M L F ODG ODG 2 PP P P P 
  
GBM 4 
   
103 426/13 55 M R F HGG HGG 3 PP P P P 
  
GBM 4 POS WEAK 1+ 
104 413/13 
5 
MON 
MCH L PO LGG LGG 2 P A A A 
 
STORIFOR
M 
DES AS 1 
   
105 430/13 4 F R 
CP 
ANGLE 
MEDULLOBLAS
TOMA 
MEDUL
LOBLAS
TOMA 
3 P P P A 
  
EP 2 
   
106 432/13 32 M L FT GLIOMA ODG 3 P P A A 
  
AA 3 
   
107 436/13 25 M R F GLIOMA 
GLIOM
A 
2 P P P A 
  
AA 3 
   
108 437/13 14 M R FP GLIOMA 
GLIOM
A 
2 P P A A 
  
PA 1 
   
109 438/13 65 M L PO HGG HGG 3 PP P P P 
  
GBM 4 
   
110 439/13 50 M L T HGG HGG 2 PP P P P 
 
SMALL 
CELL 
GBM 4 
   
111 444/13 35 F M CC SOL HGG HGG 3 PP P P A 
  
OA 2 POS WEAK 3+ 
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112 450/13 44 M R F LGG LGG 2 P P A A 
  
ODG 2 POS WEAK 3+ 
113 451/13 55 F R FP HGG HGG 3 PP P P P 
  
GBM 4 
   
114 461/13 45 F R FP LGG LGG 2 P P A A 
  
DA 2 
   
115 479/13 1 M M IV EP EP 2 P A P A 
  
AEP 3 
   
116 480/13 22 M M ID EM EP NIL 2 P P A A 
  
MPEP 1 
   
117 483/13 65 F R F LGG LGG 2 P P A A 
  
DA 2 
   
118 487/13 17 M R P LGG LGG 1 P A P A 
  
DFA 2 
   
119 489/13 3 F M PO FO 
MEDULLOBLAS
TOMA 
EPEN 2 P A P A 
  
EP 2 
   
120 491/13 29 M M PO FO EPEN EPEN 2 P P A A 
  
EP 2 
   
121 493/13 29 M R F LGG LGG 2 P P A A 
  
DFA 2 
   
122 501/13 60 F L TP GLIOMA LGG 3 PP P PP P 
  
GBM 4 
   
123 504/13 70 M R FP HGG HGG 3 PP P P P 
  
GBM 4 
   
124 512/13 16 M R F PA PA 2 P P A A 
  
PA 1 POS WEAK 2+ 
125 513/13 37 F L F HGG HGG 3 PP P A P 
 
GC GBM 4 POS WEAK 1+ 
126 514/13 60 F M BG GLIOMA HGG 1 PP P P P 
  
GBM 4 
   
127 518/13 57 M R F HGG HGG 2 PP P P P 
  
GBM 4 
   
128 521/13 60 M M 4TH VEN GLIOMA GBM 3 P P PP P 
  
GBM 4 
   
129 526/13 9 F M PO FO GLIOMA 
CELLUL
AR 
EPEN 
3 P P A A 
  
EP 2 
   
130 532/13 64 M R P HGG HGG 3 PP P P P 
  
GBM 4 
   
131 554/13 37 F L F HGG HGG 3 PP PP PP P 
 
GC GBM 4 
   
132 559/13 56 M L TP 
 
HGG 3 PP PP P P 
 
GC GBM 4 
   
133 563/13 60 F L P 
 
HGG 3 PP P PP P 
  
GBM 4 
   
134 572/13 26 F M IMSOL SOL EP 2 P P A A 
  
AEP 3 
   
135 578/13 36 M R FT 
 
LGG 2 P A A A 
  
DFA 2 
   
136 580/13 19 M R BG 
 
GG 2 P 
    
GC GG 2 
   
137 586/13 42 M L T 
 
MENIN
GIOMA 
3 PP P P P 
  
GBM 2 
   
138 594/13 56 M R BG GLIOMA DA 2 P P A A 
  
DFA 2 NEG 
 
0+ 
139 596/13 15 F M PO FO LGG LGG 2 P P A A 
  
EP 2 
   
140 /2/14/ 35 M M CC SOL HGG GBM 2 PP P P A 
  
DFA 2 
   
141 /7/14 50 M R T GLIOMA LGG 3 PP P P P 
  
GBM 4 POS WEAK 2+ 
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142 /9/14 85 M L FT HGG HGG 3 PP P P P 
  
GBM 4 
   
143 20/14 47 M L FT GLIOMA HGG 2 P P P A 
  
DA 2 
   
144 30/14 51 F R F GLIOMA HGG 3 PP P P P 
  
GBM 4 
   
145 38/14 7 F R 
CEREBEL
LUM 
LGG LGG 1 P P A A 
  
PA 1 
   
146 39/14 57 M R PO HGG HGG 2 PP P P P 
 
SMALL 
CELL 
GBM 4 
   
147 41/14 13 F M SS CP LGG 3 P P P A 
  
PA 1 NEG 
  
148 43/14 2 M M PO FO EPEN EPEN 2 P P A A 
  
EP 2 
   
149 45/14 51 M R TP LGG LGG 3 PP P P P 
  
AODG 3 
   
150 51/14 55 M L P HGG HGG 3 PP P P P 
  
GBM 4 
   
151 54/14 51 M L BG HGG HGG 3 PP P P P 
  
GBM 4 NEG 
 
0+ 
152 57/14 60 M R PO HGG HGG 3 PP P P P 
  
GBM 4 
pos 
25% 
WEAK 1+ 
153 62/14 32 M R FP HGG HGG 2 P P A A 
  
DA 2 
   
154 70/14 47 M R F HGG HGG 2 PP P P A 
  
OA 3 
   
155 73/14 63 M R FT HGG HGG 3 PP P P A 
  
AODG 2 
   
156 74/14 6 F L 
CEREBEL
LUM 
MEDULLOBLAS
TOMA 
MEDUL
LOBLAS
TOMA 
2 P P P A 
 
CLEAR 
CELL 
EP 2 
   
157 75/14 6 F M 
CEREBEL
LUM 
LGG PA 2 P P A A 
  
PA 2 
   
158 76/14 35 M M BS LGG 
MEDUL
LOBLAS
TOMA 
2 P P A A 
  
ODG 3 
   
159 88/14 35 M R ON LGG LGG 1 P P P A 
  
ODG 2 NEG 
 
0+ 
160 91/14 40 M R FTP GLIOMA HGG 2 PP P P A 
  
AA 3 
POS 
50% 
WEAK 2+ 
161 97/14 72 M L T AA HGG 3 PP P P P 
  
GBM 4 
FP 
45% 
STRO
NG 
2+ 
162 112/14 60 M M ID EM MENINGIOMA LGG 1 P P P A 
  
EP 2 
   
163 118/14 33 M L F HGG HGG 2 P P A A 
  
ODG 2 
   
164 119/14 50 M R FP HGG HGG 3 PP P P P 
  
GBM 4 
   
165 120/14 43 M R T GLIOMA LGG 1 P P P A 
  
ODG 2 
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166 123/14 35 F R FP LGG LGG 1 P P P A 
  
DA 2 
   
167 155/14 32 M M 4TH VEN GLIOMA EP 2 P P P A 
  
EP 2 
   
168 175/14 16 F M PO FO LGG LGG 1 P P A A 
  
PA 1 
   
169 176/14 2 F M PO FO LGG LGG 1 P P A A 
  
EP 2 
   
170 177/14 40 M L T LGG LGG 2 P P A A 
  
ODG 2 
   
171 188/14 45 F L F MENINGIOMA HGG 2 P P P A 
  
OA 2 
   
172 203/14 35 F R T HGG HGG 2 P P P A 
  
OA 2 NEG 
 
0+ 
173 206/14 75 M L FP ODG ODG 3 P P P A 
  
ODG 2 
   
174 212/14 60 M R P HGG HGG 3 PP P P P 
  
GBM 4 
pos 
50% 
WEAK 2+ 
175 218/14 47 M R F HGG LGG 2 P P P A 
  
ODG 2 
   
176 219/14 45 M R FP LGG LGG 2 PP P P P 
  
GBM 4 
   
177 224/14 47 F L F HGG HGG 2 P P P A 
 
RECURRE
NT 
ODG 2 
POS 
75% 
STRO
NG 
4+ 
178 225/14 35 F R TP GLIOMA HGG 2 P P A A 
  
DA 2 
   
179 230/14 40 M R T HGG LGG 3 PP P P P 
  
GBM 4 NEG 
 
0+ 
180 235/14 5 M M PO FO LGG LGG 2 P P P A 
  
PA 1 
POS 
75% 
STRO
NG 
4+ 
181 250/14 46 F R TP LGG LGG 2 P P A A 
  
ODG 2 
   
182 254/14 18 M R FP HGG HGG 2 P P P A 
  
PA 1 
   
183 256/14 53 M L FP HGG HGG 3 PP P P P 
  
GBM 4 
   
184 257/14 14 F M PO FO LGG LGG 2 P P A A 
  
PA 1 
   
185 259/14 43 M R TP HGG LGG 2 PP P P A 
  
PXA 2 NEG 
 
0+ 
186 261/14 18 M M SS PIT ADENOMA 
PIT 
ADENO
MA 
2 P P P A 
  
EP 2 
POS 
75% 
WEAK 3+ 
187 265/14 15 F R TP LGG LGG 2 P P P A 
  
PA 1 
   
188 270/14 1 M 
 
F HGG HGG 2 PP P P A 
  
EP 2 
   
189 279/14 35 M R F LGG HGG 2 P P P A 
  
ODG 2 NEG 
 
0+ 
190 285/14 60 M R F GLIOMA HGG 3 PP P P P 
  
GBM 4 
   
191 287/14 21 F L TP GG LGG 3 P A A A 
  
GG 2 
   
192 297/14 31 M M IMSOL LGG LGG 2 P P A A 
  
DFA 2 
   
193 299/14 23 M L T LGG LGG 2 P P P A 
  
DFA 2 
   
194 308/14 24 M R FP HGG HGG 3 PP P P P 
  
GBM 4 
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195 309/14 56 M R PO HGG HGG 3 PP P P A 
  
AA 3 NEG 
 
0+ 
196 323/14 24 F R P LGG LGG 3 P P P A 
  
ODG 2 
   
197 324/14 42 M L T LGG LGG 3 P P A A 
  
DA 2 
   
198 329/14 45 F M IM SOL GLIOMA LGG 3 PP P P A 
  
DA 2 
   
199 331/14 42 F L F GLIOMA LGG 3 P P P P 
  
ODG 2 
   
200 334/14 29 M M IMSOL EPEN EPEN 2 P P A A 
  
EP 2 
   
201 342/14 55 M R PO METS EPEN 2 P P P A 
  
GBM 4 
   
202 347/14 44 F L F GLIOMA HGG 3 PP P P A 
  
AA 3 
POS 
70% 
STRO
NG 
3+ 
203 355/14 10 F M 4TH VEN 
MEDULLOBLAS
TOMA 
LGG 2 P A A A 
  
PA 1 
   
204 357/14 61 F L F GBM HGG 3 PP P P A 
  
AA 3 
   
205 364/14 54 F L F GBM GBM 3 PP P P P 
  
GBM 4 
   
206 366/14 30 M R T LGG LGG 2 P P A A 
  
DFA 2 
   
207 374/14 4 F R F LGG LGG 2 P P A A 
  
PA 1 
   
208 375/14 15 F M IM SOL HGG HGG 1 P P A A 
 
TANYCYTI
C 
EP 2 
   
209 377/14 11 F L FP LGG LGG 1 P P P A 
  
PA 1 
   
210 382/14 45 M R F LGG LGG 1 P P A A 
  
ODG 2 
   
211 387/14 14 F L F HGG HGG 3 PP P P P 
  
AOA 3 
   
212 401/14 49 M M CC SOL HGG HGG 3 PP P P P 
  
GBM 4 
   
213 404/14 8 F M PO FO MEDULLO 
MEDUL
LOBLAS
TOMA 
2 PP P P A 
  
PA 1 
   
214 412/14 25 M R FT LGG LGG 2 P P P A 
  
DA 2 
   
215 413/14 50 M L F EPEN EPEN 2 P P P A 
  
ODG 2 
   
216 416/14 40 F R PO HGG HGG 3 PP PP P P 
  
GBM 4 
   
217 418/14 18 M M PO FO LGG LGG 2 P P A A 
  
PA 1 
   
218 419/14 56 F R TP LGG LGG 2 PP PP PP P 
  
GBM 4 
   
219 428/14 64 M R TP HGG HGG 3 PP PP P P 
  
GBM 4 
   
220 430/14 40 M R F HGG HGG 3 PP P P P 
  
GBM 4 
   
221 432/14 40 M L TP HGG HGG 3 PP PP P P 
  
GBM 4 
   
222 439/14 36 M L F LGG LGG 2 P P A A 
  
PA 1 
POS 
85% 
WEAK 4+ 
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223 443/14 39 F L T GLIOMA HGG 3 PP P P P 
  
GBM 4 
   
224 444/14 55 F R F HGG HGG 3 PP P P P 
  
GBM 4 
   
225 447/14 46 M L T HGG HGG 3 PP P P A 
  
AEP 3 
   
226 452/14 11 M R F LGG HGG 2 PP P A A 
  
PXA 2 
   
227 457/14 36 F L T HGG HGG 3 PP P P P 
  
GBM 4 
   
228 465/14 38 M R F HGG HGG 2 PP P A A 
  
ODG 2 
   
229 468/14 55 F R LAT VEN LGG LGG 2 P P P A 
  
DA 2 
   
230 469/14 45 F R TP LGG LGG 3 P P P A 
  
ODG 2 
   
231 475/14 40 M L P LGG LGG 3 PP P P P 
  
GBM 4 
pos 
50% 
STRO
NG 
2+ 
232 480/14 50 F L P METASTASES HGG 2 PP PP PP P 
  
GBM 4 
   
233 483/14 36 F R F GRANULOMA 
GLIOM
A 
3 P P P A 
  
DA 2 
   
234 489/14 30 F L F HGG HGG 3 PP P P A 
  
AA 3 
   
235 491/14 70 M M ED SOL HGG HGG 3 P P A A 
  
DA 2 
   
236 499/14 46 F R T HGG HGG 2 P P P A 
  
AA 3 
POS 
50% 
WEAK 2+ 
237 508/14 8 F R 
CEREBEL
LUM 
LGG LGG 2 P P A A 
  
PA 1 
POS 
70% 
STRO
NG 
3+ 
238 510/14 52 M L T GLIOMA HGG 3 PP P P P 
  
GBM 4 
   
239 513/14 28 M L FT HGG HGG 2 P P A A 
  
ODG 2 
   
240 511/14 49 L FP FP HGG HGG 2 P P P A 
  
PXA 2 
   
241 519/14 53 M M CC SOL HGG HGG 2 P P A A 
  
DA 2 
   
242 536/14 78 F L TP LGG HGG 3 PP P P P 
  
GBM 4 NEG 
 
0+ 
243 539/14 6 F M IM SOL LGG LGG 2 P P A A 
  
PA 1 NEG 
 
0+ 
244 547/14 78 F L TP LGG LGG 3 PP P P P 
  
GBM 4 
   
245 552/14 36 F L PO HGG HGG 3 PP P P P 
  
GBM 4 
   
246 555/14 28 M L PO LGG LGG 2 P P A A 
 
RECURRE
NT 
AA 3 
   
247 559/14 26 M L TP HGG HGG 3 PP P P P 
  
GBM 4 
   
248 563/14 4 F M PO FO PA PA 2 P P P P 
  
PA 1 
   
249 578/14 60 M R F GLIOMA HGG 3 PP P P P 
  
GBM 4 
   
250 580/14 40 M L PO GLIOMA 
R..GLIO
SIS 
3 P P A A 
  
DA 2 
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251 583/14 11 F L FT HGG HGG 3 PP PP P A 
  
AEP 3 
   
252 588/14 35 M R FP EPEN EPEN 2 P P P A 
  
EP 2 
   
253 589/14 25 M L F LGG LGG 3 PP P P A 
  
ODG 2 
   
254 591/14 45 F R F HGG HGG 3 PP P P P 
  
GBM 4 
   
255 606/14 75 F R FT GBM HGG 3 PP PP P PP 
  
GBM 4 
   
256 612/14 52 M R TP GLIOMA GBM 3 PP PP PP P 
  
GBM 4 
   
257 618/14 50 M R T METS HGG 3 PP PP P P 
  
GBM 4 
   
258 628/14 38 F L FTP 
TUBERCULOM
A 
LGG 2 P P A A 
  
PA 1 
   
259 631/14 50 F R PO METASTASES 
GRANU
LOMA 
2 P PP P PP 
  
GBM 4 
   
260 635/14 8 F M PO FO EPEN EP 2 P P A A 
  
EP 2 
   
261 646/14 50 F M CC SOL LGG LGG 2 P P P A 
  
OA 2 
   
262 651/14 60 M L F ABCESS HGG 3 PP P PP PP 
  
GBM 4 
   
263 652/14 83 M L TP METASTASES GBM 3 P PP P PP 
  
GBM 4 
   
 
  
KEY TO MASTER CHART 
 
Age  - Entered in years 
Sex M - MALE 
 F - FEMALE 
Side R - right 
 L - left 
 M - midline 
Site : 
F              - FRONTAL    
FP  - FRONTOPARIETAL 
FT  - FRONTO TEMPORAL 
FTP  - FRONTOTEMPOROPARIETAL 
T  - TEMPORAL 
TP  - TEMPOROPARIETAL 
P  - PARIETAL 
O  - OCCIPITAL 
PF  - PARIETOFRONTAL 
BS  - BRAIN STEM 
CC  - SOLCORPUS CALLOSUM 
 IV   - INTRAVENTRICULAR 
   4TH VENTRICLE 
PO FO              - POSTERIOR FOSSA 
ON  - OPTIC NERVE 
OC  - OPTIC CHIASMA 
BG  - BASAL GANGLIA 
SS  - SUPRASELLAR 
ED SOL - EXTRA DURAL SOL 
ID IM SOL - INTRADURAL INTRAMEDULLARY SOL 
ID EM               - INTRADURAL EXTRAMEDULLARY SOL 
 
  
RADIOLOGY& SQUASH 
LGG   - LOW GRADE GLIOMA 
HGG   - HIGH GRADE GLIOMA 
SOL   - SPACE OCCUPYING LESION 
PA    - PILOCYTIC ASTROCYTOMA 
DA    - DIFFUSE ASTROCYTOMA 
ODG    - OLIGODENDROGLIOMA 
AA    - ANAPLASTIC ASTROCYTOMA 
MEDULLO  - MEDULLOBLASTOMA 
PIT ADENOMA - PITUITARY ADENOMA 
CP    - CRANOPHARYNGIOMA 
GBM    - GLIOBLASTOMA MULTIFORME 
METS   - METASTASES 
PNET   - PRIMITIVE NEURECTODERMAL TUMOUR 
 
CELLULARITY 
 1 - LOW 
 2 - MODERATE 
 3 - HIGH 
 
NP-NUCLEAR PLEOMORPHISM 
 1+-P  MILD NUCLEAR PLEOMORPHISM 
 2+  PP marked NUCLEAR PLEOMORPHISM 
 
MITOSES 
 A-ABSENT 
 P-PRESENT 
 VP-VASCULAR  PROLIFERATION 
 A-ABSENT 
 P-PRESENT 
 
NEC-NECROSES 
 A-ABSENT 
 P-PRESENT 
 
CA-CALCIFICATION  
HPE DIGNOSIS 
 PA : pilocytic astrocytoma  
 DFA : diffusefibrillary astrocytoma 
 DA :  diffuse astrocytoma 
 ODG : oligodendroglioma 
 EPEN : ependymoma 
 MPEP - myxopapillaryependymoma 
 T -  ependymoma-tanycyticependymoma 
 OA - oligoastrocytoma 
 PXA ; PleomorphicXanthoastrocytoma 
 OA : oligoastrocytoma 
 GG - ganglioglioma 
 Des as  - desmoplastic astrocytoma 
 AODG  - anaplastic oligodendroglioma 
 AA : anaplastic astrocytoma 
 GBM : Glioblastomamultiforme 
 
Whograde 
GRADE I  : Neoplasms with low proliferative tendency 
GRADE II  : Neoplasms with cytological atypia alone 
GRADE III  : Neoplasms with anaplasia and mitotic activity 
GRADE IV  : Neoplasms with micro vascular proliferation and/ornecrosis  
 
IHC 
CD117 –POS-POSITIVE 
         NEG –NEGATIVE 
CD117 STAINING INTENSITY  
WEAK ,MOD-MODERATE,STRONG 
CD117  SCORE 
score 0  - no immunoreactive cells 
score 1+-1-10% 
score 2+ 11-50% 
score3+ 51-75% 
score4+ more than 75% (128) 
